Miscellaneous Uses of Anabolic Steroids

  • H. Kopera
Part of the Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology book series (HEP, volume 43)

Abstract

The value of anabolic steroids (AST) in the treatment of several more or less well-defined indications has been described in other sections of this book. The aim of the present chapter is to list, discuss, and where possible evaluate the remaining available data on the therapeutic use of these preparations.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adám, G., Miltényi, L., Dézsi, Z., Jóna, G.: Die Wirkung von Nandrolone-Dekanoat auf den Eisenumsatz des Organismus nach Bestrahlung. Strahlentherapie 136, 113–115 (1968).PubMedGoogle Scholar
  2. Adám, G., Miltényi, L., Molnár, A.: Die Wirkung von Nandrolon-Dekanoat und Eisenpräparaten auf das Blutbild von bestrahlten Patienten. Strahlentherapie 141, 696–698 (1971).PubMedGoogle Scholar
  3. Adda, M.: Etude sur 50 malades immobilisés traités par le stromba pendant deux ans. Sem. Hôp. Paris 75–76 (1965).Google Scholar
  4. Aepli, R.: Potentialisation de l’action anti-inflammatoire des corticosteroides par le Dianabol dans le traitement au long cours de l’asthme bronchique. Schweiz. med. Wschr. 94, 53–57 (1964).PubMedGoogle Scholar
  5. Agapova, E.N., Tkachenko, A.M., Krutovskaya, O.V.: Use of anabolic preparations in atherosclerotic cardiosclerosis. Klin. Med. (Moskau) 52, 42–44 (1974).Google Scholar
  6. Ahlendorf, W., Kob, D.: Stationäre Nachbehandlung von Patienten mit reseziertem Magenkarzinom. Arch. Geschwulstforsch. 36, 64–75 (1970).PubMedGoogle Scholar
  7. Ahrends, H.: Beitrag zum familiären Vorkommen und zur Therapie der Cystinose. Z. Kinder-heilk. 99, 101 (1967).Google Scholar
  8. Akzhigitov, G.N., Usatova, I.Y., Kaplan, L.D.: Use of glucocorticoid and anabolic hormones in the treatment of acute pancreatitis. Terap. Arkh. 43, 52–57 (1971).Google Scholar
  9. Albanese, A.A.: Newer methodology in the clinical investigation of anabolic steroids. J. new Drugs 5, 208–224 (1965).PubMedGoogle Scholar
  10. Albanese, A.A., Lorenze, E.J., Orto, L.A., Smullyan, J.L.: Nutritional and metabolic effects of some newer steroids. N.Y. St. J. Med. 65, 2116–2125 (1965).Google Scholar
  11. Albanese, A.A., Woodhull, M.L., Orto, L.A., Zavattaro, D.N., Wein, E.H.: Steroid and dietary effects on blood lipids in elderly persons. Nutr. Rep. Intern. 1, 231–242 (1970).Google Scholar
  12. Alberto, S., Colongo, P., Brusasco, L.: Comments on the anti-asthenic and anti-depressive properties of androstanazol in geriatrics. Minerva med. 59, 2288–2293 (1968).PubMedGoogle Scholar
  13. Al-Hussaini, M., McGillis, A., Frank, I.N., McDonals, D.F.: Anabolic effect of norethandro-lone and nandrolone phenpropionate in uremic rats. Invest. Urol. 3, 537–545 (1965).Google Scholar
  14. Allenby, F., Jeyasingh, K., Calnan, J.: Ethyloestrenol and postoperative venous thrombosis. Lancet 1973II, 38–39.Google Scholar
  15. Almér, L.-O., Pandolfi, M., Nilsson, I.M.: Diabetic retinopathy and the fibrinolytic system. Diabetes 24, 529–534 (1975).PubMedGoogle Scholar
  16. Aly, F.W.: Klinische Erfahrungen mit einem nichtvirilisierenden, oral wirksamen Testosteron-Derivat (Dehydro-17-Methyltestosteron). Med. Welt 47, 2468–2473, Part 1 (1961)PubMedGoogle Scholar
  17. Aly, F.W.: Klinische Erfahrungen mit einem nichtvirilisierenden, oral wirksamen Testosteron-Derivat (Dehydro-17-Methyltestosteron). Med. Welt 48, 2513–2520, Part 2 (1961).PubMedGoogle Scholar
  18. Ambrus, C.M., Ambrus, J.L.: Myeloid regeneration after whole body irradiation, autologous bone marrow transplantation, and treatment with an anabolic steroid. J. Med. Exp. Clin. 6, 27–32 (1975).Google Scholar
  19. Ambrus, J.L., Mirand, E.A.: Effect of autologous bone marrow transplantation and an anabolic steroid on erythropoietin production and hemopoietic recovery after whole body irradiation and treatment with alkylating agents. J. Med. 4, 65–81 (1973).PubMedGoogle Scholar
  20. Ammedick, U., Konrad, R.M., Gotzen, E.: Über die Wirksamkeit anaboler Steroide in der postoperativen Phase. Med. Ernähr. 9, 121–123 (1968).Google Scholar
  21. Antonini, F.M., Verdi, G.: Investigations concerning a new anabolic synthetic steroid: oxy-metholone. Behaviour of some lipid fractions of the serum. G. Geront. 9, 1051–1065 (1961).Google Scholar
  22. Ariel, G., Saville, W.: The effect of anabolic steroids on reflex components. Med. Sci. Sports 4, 120–123 (1972).Google Scholar
  23. Arthur, K.: Some aspects of chemotherapy in breast carcinomatosis. Clin. Radiol. 19, 351–356 (1968).PubMedGoogle Scholar
  24. Babel, J.: Le traitement de la rétinopathie diabétique par les anabolisants. Méd. et Hyg. 23, 485–486 (1965).Google Scholar
  25. Badalyn, L.O., Dunaevskaya, G.N., Sitnikov, V.T.: Treatment of progressive muscular dystrophy. Zh. Nevropatol. Psikhiatr. 75, 1317–1323 (1975).Google Scholar
  26. Bär, W., Usbeck, W.: Zur oralen Anwendung anaboler Hormone bei magenlosen Patienten. Dtsch. Gesundh.-Wes. 26, 1007–1009 (1971).Google Scholar
  27. Bär, W., Usbeck, W.: Orale Anabolikatherapie bei magenlosen Patienten. Zbl. Chir. 99, 1306–1311 (1974).PubMedGoogle Scholar
  28. Baker, C.D., Baum, G.: Use of an anabolic drug in malnutrition in the aged. Practitioner 193, 683–685 (1964).Google Scholar
  29. Balakhovsky, I.S., Okhotsky, V.P., Fedorov, J.V., Doronin, E.I., Yakovleva, I.P.: Indications and applications of an anabolic steroid preparation in clinical orthopaedics. Klin. Med. (Moskau) 50, 110–114 (1972).Google Scholar
  30. Balmes, A., Dauverchain, J., Othoniel, J., Juanchich, J.: Intérêt du Durabolin (phenylpropio-nate de 19-norandrosténolone) dans le traitement des pneumopathies aigues. Vie méd. 29, 3527–3536 (1969).Google Scholar
  31. Barnes, H.D., Overton, J., Sweet, R.D.: Familial cutaneous porphyria. Brit. J. Derm. 77, 130–136 (1965).PubMedGoogle Scholar
  32. Barwick, D.D., Newell, D.J., Walton, J.N.: Methandrostenolone and nandrolone decanoate in muscular dystrophy. A controlled trial. Neurology 13, 12–23 (1963).Google Scholar
  33. Bauer, A., Krammer, H.: Erfahrungen mit Stromba in der Geriatrie. Ther. Umsch. 21, 194–207 (1964).PubMedGoogle Scholar
  34. Bauer, B., Antener, I.: Eine wirksame diätetische und medikamentöse Cystinosebehandlung. Helv. paediat. Acta 21, 19–50 (1966).PubMedGoogle Scholar
  35. Beaumont, J.-L., Carlson, L.A., Cooper, G., Fejfar, Z., Fredrickson, D.S., Strasser, T.: Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull. Wld. Hlth. Org. 43, 891 (1970).Google Scholar
  36. Beaumont, P., Hollows, F.G.: Classification of diabetic retinopathy, with therapeutic implications. Lancet 1972II, 419–424.Google Scholar
  37. Becker, J., Kärcher, K.H., Kleibel, F.: Die zusätzliche Behandlung und Verlaufsbeobachtung während der Strahlentherapie und cytostatischen Behandlung. Radiologe 6, 159–175 (1966).PubMedGoogle Scholar
  38. Beckmann, R.: Erfahrungen mit anabolen Steroiden bei Myopathien. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  39. Beckmann, R.: Discussion on: Dowben, R.M., Anabole Steroide bei Myopathien. Myopathien. Stuttgart: Georg Thieme Verlag 1965.Google Scholar
  40. Bei, P.I.: The use of nerobol in the treatment of patients with rheumatic heart defects and circulatory failure. Klin. Med. (Moskau) 46, 104–106 (1968).Google Scholar
  41. Bei, P.I.: The effect of nerobol on the contractile capacity of the myocardium. Klin. Med. (Moskau) 50, 69–74 (1972).Google Scholar
  42. Beiglböck, W., Brummund, W.: Über das Problem der anabolen Wirkung von Testosteron Derivaten (Bericht über Erfahrungen mit Dianabol). Med. Welt 22, 1192–1203 (1960).Google Scholar
  43. Bekény, G., Kraft, F., Lang, S.: Die Anwendung von Durabolin (19-Nor-Androstenolon-phenylpropionat) in der Behandlung der Dystrophia musculorum progressiva. Nervenarzt 31, 118–123 (1960).PubMedGoogle Scholar
  44. Benda, L., Geyer, G.: Untersuchungen über den Eiweiß-Stoffwechsel bei Leberkranken unter anabol wirksamen Steroiden. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  45. Berger, H., Antener, J., Brechbühler, T., Stalder, G.: Zum Problem der Cystinose. Beobachtungen über den Cystinnachweis im Serum und therapeutische Erfahrungen mit Penicillamin und anabolem Hormon. Ann. Paediat. (Basel) 202, 465–482 (1964).Google Scholar
  46. Bergmann, M.: Die Wirkung von „Deca-Durabolin” auf den Reststickstoffspiegel im Blut. Med. Welt 10, 538–543 (1962).PubMedGoogle Scholar
  47. Berkowitz, D.: Anabolic agents in gastroenterology. Paper presented at a Symposium on Anabolic Therapy, Detroit, March 1962.Google Scholar
  48. Berkowitz, D., Spitzer, J., Likoff, W.P.: Practical significance of serum triglycerides and radioactive fat tolerance: their relation to current therapy for hypercholesterolemia. Amer. J. Cardiol. 10, 198 (1962).PubMedGoogle Scholar
  49. Besa, E.C., Gorshein, D., Gardner, F.H.: Androgens and human blood volume changes. Comparison in normal and various anemic states. Arch. intern. Med. 133, 418–425 (1974).PubMedGoogle Scholar
  50. Bew, K.: A double-blind trial of an anabolic steroid in eighteen elderly women. Practitioner 194, 530–534 (1965).PubMedGoogle Scholar
  51. Bielawiec, M., Perzanowski, A., Mysliwiec, M.: Long term therapy of patients suffering from occlusive arterial disease with combined therapy with phenformin and stanozolol. Throm-bos. Diathes. haemorrh. 34, 916–917 (1975).Google Scholar
  52. Bielawski, W.: The effect of oxyterracin on rat liver cell in the course of gravidity and estradiol and durabolin treatment (2nd communication). Pol. Arch. Med. wewnet. 40, 15–20 (1968).PubMedGoogle Scholar
  53. Bierich, J.R.: Erfahrungen mit Anabolika bei der progressiven Muskeldystrophie im Kindesalter. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  54. Bierich, J.R., Grüttner, R., Landbeck, G.: Therapeutic effects of anabolic steroids in progressive muscular dystrophy. Paper at the 10th Internat. Congress of Pediatrics, Lisbon, 1962.Google Scholar
  55. Blagg, C.R., Parsons, F.M.: Use of norethandrolone in acute renal failure from obstetric causes. Lancet 1960II, 577–581.Google Scholar
  56. Blagg, C.R., Parsons, F.M.: Early dialysis and anabolic steroids in acute renal failure. Amer. Heart J. 61, 287–291 (1961).Google Scholar
  57. Blair, A.J., Morgen, J.C., Beck, J.C.: The plasma 17-hydroxycorticosteroid levels in acute and chronic renal failure. Canad. J. Biochem. 39, 1617–1624 (1961).PubMedGoogle Scholar
  58. Blahnikova, L.: A propos de l’indication des stéroides anabolisants dans le traitement des lésions hépatiques chroniques. Gastroenterologie 107, 354–359 (1967).Google Scholar
  59. Blahnikova, L., Horky, J.: Einfluß der anabolen Steroide auf den Eiweißstoffwechsel bei verschiedener Proteinzufuhr bei chronisch Leberkranken. Z. Ernährungsw. Suppl. 13, 105–112 (1972).Google Scholar
  60. Blasius, R., Käfer, K., Seitz, W.: Untersuchungen über die Wirkung von Testosteron auf die contractilen Strukturproteine des Herzens. Klin. Wschr. 34, 324–326 (1956).PubMedGoogle Scholar
  61. Blasius, R., Käfer, K., Seitz, W.: Untersuchungen über die Abhängigkeit von androgener Wirkung und proteinaufbauendem Effekt der Steroid-Hormone auf die contractilen Muskelproteine des Herzens. Klin. Wschr. 35, 308–310 (1957).PubMedGoogle Scholar
  62. Boillat, J.E., Saxena, B.M., Lehmann, H.E., Ban, T.A.: Combined administration of thioridazine, nicotinic acid and fluoxymesterone in the treatment of geriatric patients. Curr. ther. Res. 13, 541–544 (1971).Google Scholar
  63. Bolch, O.H., Warren, J.C.: Induction of premature menstruation with catatoxic steroids. Amer. J. Obstet. Gynec. 111, 1107–1110 (1971).PubMedGoogle Scholar
  64. Bond, W.H., Arthur, K.: Some observations on the use of cytotoxic drugs and anabolic steroids in the treatment of breast carcinomatosis. Paper read at a Symposium at the University Dept. of Surgery, Royal Infirmary, Sheffield, Nov. 1966.Google Scholar
  65. Borgman, R.F.: Increased survival-time in dystrophic mice treated with methylandrostenediol dienanthoylacetate. Nature (Lond.) 197, 1304 (1963).Google Scholar
  66. Bors, E., Comarr, A.E.: Neurological urology. Basel-München-Paris-New York: S. Karger 1971.Google Scholar
  67. Bottero, A., Lops, M.: L’impiego della dimetazina nelle bronchopneumatopatie specie senile. Gazz. med. ital. 123, 111 (1964).PubMedGoogle Scholar
  68. Bour, H., Tutin, M., Dorf, G., Guy-Grand, B.: La rétinite diabétique: pathogénie et thérapeutique. Ent. Bichat. 1967, 213–220.Google Scholar
  69. Bourdakos, N., Wolf, S.: Creatine and muscular dystrophy; relationship of creatine-creatinine metabolism to diet and drugs. Arch. Neurol. 6, 439–450 (1962).PubMedGoogle Scholar
  70. Bourgeois, M., Vincent, D.: L’oxymétholone. Essai thérapeutique sur 50 malades de neuropsychiatrie. J. Méd. Bordeaux 141, 260–263 (1964).PubMedGoogle Scholar
  71. Brambilla, F., Giardini, M., Russo, R.: Prospects for a pharmacological treatment of phenylketonuria. Dis. nerv. Syst. 36, 257–260 (1975).PubMedGoogle Scholar
  72. Brennan, M.F., Tweedle, D., Moore, F.D.: Body nitrogen after trauma. Lancet 1975I, 38–39.Google Scholar
  73. Bretan, M., Szabo, Z., Jakab, L.: Beeinflussung der diabetischen Retinopathie mit Nor-Andro-stenolonphenylpropionat und Decanoat. Orv. Hetil. 105, 1171–1174 (1964).PubMedGoogle Scholar
  74. Brodsky, I.: The role of androgens and anabolic steroids in the treatment of cancer. Semin. Drug Treatm. 3, No. 1, 15–25 (1973).Google Scholar
  75. Brodsky, I., Dennis, L.H., Kahn, S.B.: Testosterone enanthate (NSC-17591) as a bone marrow stimulant during cancer chemotherapy: Preliminary report. Cancer Chemother. Rep. 34, 59 (1964).PubMedGoogle Scholar
  76. Brodsky, I., Kahn, S.B.: The effect of androgens on cancer chemotherapy. In: Cancer Chemotherapy: Basic and Clinical Applications, 275–287. New York: Grune & Stratton 1967.Google Scholar
  77. Brodsky, I., Kahn, S.B., Conroy, J.F.: The effects of androgens on cancer chemotherapy. In: Cancer Chemotherapy II, 303–314. New York: Grune & Stratton 1972.Google Scholar
  78. Brown, I.A., James, E.M.: Nandrolone-phenpropionate in progressive muscular dystrophy. A preliminary report. Arch. Pediat. 78, 421–431 (1961).Google Scholar
  79. Brown, I.K., Downie, R.J., Haggart, B., Littler, J., Murray, G.H., Robb, P.M., Santer, G.J.: Pharmacological stimulation of fibrinolytic activity in the surgical patient. Lancet 1971I, 774–776.Google Scholar
  80. Browne, P.A.: The treatment of secondary deposits in bone from carcinoma of the breast with P32 and durabolin. Paper read at a Symposium at the University Dept. of Surgery, Royal Infirmary, Sheffield, Nov. 1966.Google Scholar
  81. Brückner, R.: Lentopathie und Retinopathie, Signale im Diabetes und Prädiabetes. Praxis 54, 746–755 (1965).PubMedGoogle Scholar
  82. Brügel, H.: Klinische Erfahrungen bei der Behandlung untergewichtiger Magenresezierter. Aktuelle Kongreß-Berichte 1, 16. Ärztlicher Fortbildungskurs Bad Kissingen. Berlin: Medicus Verlag 1965.Google Scholar
  83. Brügger, W.: Zur Beeinflussung der hämatotoxischen Effekte von Cyclophosphamid durch das anabole Steroid Nandrolonphenylpropionat. Dissertation, Heidelberg, 1967.Google Scholar
  84. Bruhn, H.D., Jipp, P., Okoye, S., Oltmann, A.: Hypofibrinolyse beim akuten Myokardinfarkt. Med. Klin. 69, 1951–1955 (1974).PubMedGoogle Scholar
  85. Buchner, H.: Zur Frage der hormonalen Beeinflussung des posttraumatischen Eiweißverlustes. Wien. med. Wschr. 111, 576–580 (1961).PubMedGoogle Scholar
  86. Buckert, D.: Dianabol in der Geriatrie. Dtsch. med. J. 15, 25–27 (1964).PubMedGoogle Scholar
  87. Bürgi, H., Regit, J.: Zur Ergänzung der tuberkulostatischen Behandlung mit einer Vitamin-Mineral-Anabolikum-Kombination. Praxis 58, 873–874 (1969).PubMedGoogle Scholar
  88. Bullough, W.S.: Mitotic and functional homeostasis—a speculative review. Cancer Res. 25, 1683–1727 (1965).PubMedGoogle Scholar
  89. Bullough, W.S., Homan, J.D.H., Laurence, E.B., Overbeek, G.A.: In vitro Untersuchung an der Mäuseohrepidermis über die von Dexamethason induzierte und von Nandrolondeca-noat aufgehobene Mitosehemmung. J. Endocr. 41, 453–454 (1968).PubMedGoogle Scholar
  90. Burn, J.I., Cooke, W.M.: Effect of nandrolone phenylpropionate (NSC-23162E) on the bone marrow suppression caused by cyclophosphamide (NSC-26271): A clinical trial. Cancer Chemother. Rep. 58, 867–870 (1974).PubMedGoogle Scholar
  91. Burnett, P.C.: A steroidal pyrazole as an anabolic agent in the treatment of geriatric mental patients. J. Amer. Geriat. Soc. 11, 979–982 (1963).PubMedGoogle Scholar
  92. Buttenberg, D.: Anabolika bei gynäkologischen Karzinomen. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  93. Castro, J.E., Medawar, P.B., Hamilton, D.N.H.: Orchidectomy as a method of immunopotentiation in mice. Ciba Found. Symp. 18, 237–258 (1973).Google Scholar
  94. Ceccarelli, G.: Anabolizzante e lesione renali. Arch. Sci. med. 120, 374–384 (1965).Google Scholar
  95. Cendrowski, W., Kuran, W.: Results of combined administration of anabolic steroids in patients with multiple sclerosis. Neurol. Neurochir. Psychiat. pol. 6, 573–576 (1972).Google Scholar
  96. Cesnik, H., Fink, E.: Klinische Untersuchungen eines neuen anabolen Steroids. Med. Klin. 59, 1430–1433 (1964).PubMedGoogle Scholar
  97. Chakrabarti, R.: Comparative effects of platelet adhesiveness by phenformin combined with ethylestrenol or stanozolol. Acta Univ. Carol. Med. (Monogr.) (Praha) 53, 261–262 (1972).Google Scholar
  98. Chakrabarti, R., Evans, J.F., Fearnley, G.R.: Effects on platelet stickiness and fibrinolysis of phenformin combined with ethyloestrenol or stanozolol. Lancet 1970I, 591–593.Google Scholar
  99. Chakrabarti, R., Fearnley, G.R.: Phenformin plus ethyloestrenol in survivors of myocardial infarction. Three year pilot study. Lancet 1972II, 556–559.Google Scholar
  100. Chakrabarti, R., Fearnley, G.R.: Pharmacological fibrinolysis in diabetes mellitus. Diabetologia 10, 19–22 (1974).PubMedGoogle Scholar
  101. Chakrabarti, R., Fearnley, G.R., Evans, J.F.: Reduction of platelet stickiness by phenformin plus ethyloestrenol. Lancet 1967II, 1012–1014.Google Scholar
  102. Chakrabarti, R., Fearnley, G.R., Hocking, E.D., Delitheos, A., Clarke, G.M.: Fibrinolytic activity related to age in survivors of myocardial infarction. Lancet 1966I, 573.Google Scholar
  103. Chapuy, P., Convert, G.: Clinical study of strombaject in geriatrics. Cah. méd. Lyon 49, 36 (1973).Google Scholar
  104. Cheng, H., Kohner, E.M., Keen, H., Blach, R.K., Hill, D.W.: Photocoagulation in treatment of diabetic maculopathy. Lancet 1975II, 1110–1113.Google Scholar
  105. Choi, E.S.K., Chung, T., Morrison, R., Myers, C., Greenberg, M.S.: Hypertriglyceridemia in hemodialysis patients during oral dromostanolone therapy for anemia. Amer. J. clin. Nutr. 27, 901–904 (1974).PubMedGoogle Scholar
  106. Christensen, L.R., MacLeod, C.M.: A proteolytic enzyme of serum: characterization, activation, and reaction with inhibitors. J. gen. Physiol. 28, 559–568 (1945).PubMedGoogle Scholar
  107. Christl, H., Brommer, R., Wilde, W., Bork, U.: Moderne eiweißanabole Therapie der täglichen Praxis (I). Fortschr. Med. 80, 667–703 (1962).Google Scholar
  108. Cicchitti, L., Labat, J.C., Introna, L., Minuchin, O.: Accion del deca-noato de nandrolona sobre la retinopatia diabetica. Paper read at Tercer Congreso Argentino de Nutricion, Mendoza, Sept. 1966.Google Scholar
  109. Ciświcka-Sznajderman, M., Berent, H., Rymaszewski, Z.: The effect of combined treatment with phenformin and stanazolol on blood lipids and fibrinolytic activity in patients with hypertriglyceridaemia. Atherosclerosis 19, 153–159 (1974).PubMedGoogle Scholar
  110. Cohen, W.D., Higano, N., Robinson, R.W., LeBeau, R. J.: Changes in serum lipids and urinary ketosteroids during oral and intramuscular administration of androsterone. J. clin. Endocr. 21, 1208 (1961).PubMedGoogle Scholar
  111. Cole, M.P., Todd, I.D.H., Wilkinson, P.M.: Cyclophosphamide and nandrolonedecanoate in the treatment of advanced carcinoma of the breast—results of a comparative controlled trial of the agents used singly and in combination. Brit. J. Cancer 27, 396–399 (1973).PubMedGoogle Scholar
  112. Comar, O.B.: Nuove osservazioni sull’impiego degli steroidi anabolizzanti negli iperazotemici cronici. Minerva urol. 21, 69–74 (1969).PubMedGoogle Scholar
  113. Cooke, W.M., Burn, J.I.: The effect of nandrolone phenylpropionate (Durabolin) on the bone-marrow suppression caused by cyclophosphamide. Brit. J. Surg. 58, 302–303 (1971).PubMedGoogle Scholar
  114. Cooper, I.S., Rynearson, E.H., McCarty, C.S.: Testosterone propionate as a nitrogen-sparing agent after spinal cord injury. J. Amer. med. Ass. 145, 549–553 (1951).Google Scholar
  115. Corona, R.G.: Oximetolona en gastroectomizados. Rev. Med. Mex. 44, 193–199 (1964).Google Scholar
  116. Cottier, P.: Die Anwendung von katabolen und anabolen Hormonen bei Nierenkrankheiten. Dtsch. med. J. 13, 329–334 (1962).PubMedGoogle Scholar
  117. Craig, P.E.: Preliminary report of a long acting anabolic agent, nandrolone decanoate. Clin. Med. 69, 5, 1154–1156 (1962).Google Scholar
  118. Cunliffe, W.J.: An association between cutaneous vasculitis and decreased blood-fibrinolytic activity. Lancet 1968I, 1226–1228.Google Scholar
  119. Cunliffe, W.J., Dodman, B., Roberts, B.E.: Clinical and laboratory double-blind investigation on the effect of fibrinolytic therapy in patients with cutaneous vasculitis. Ann. rheum. Dis. 32, 591–592 (1973).PubMedGoogle Scholar
  120. Cunliffe, W.J., Menon, I.S.: Treatment of Behçet’s syndrome with phenformin and ethyl-oestrenol. Lancet 1969I, 1239–1240.Google Scholar
  121. Dam, F.E., van, Gribnau Overkamp, M.J.H., Benraad, T.J., Haanen, C.A.M.: Over de invloed van enkele geneesmiddelen op het effect en de verwerking van net indirecte anticoa-gulans ethylbiscoumacetaat. Ned. T. Geneesk. 113, 55–56 (1969).Google Scholar
  122. Danowski, T.S., Sabeh, G., Vester, J.W., Sarver, M.E., Sunder, J.H.: Muscular dystrophy. Arch. intern. Med. 115, 294 (1965).PubMedGoogle Scholar
  123. Danysz, A., Kocmierska-Grodzka, D., Panek, R., Matzkovyak, J.: Antimetabolites in the treatment and prophylaxis of radiation sickness. Med. Radiol. Moskva 13, 3–9 (1968).Google Scholar
  124. Dardenne, M.U.: Treatment of retinopathia diabetica with anabolic steroids and light coagulation, and the effect of this therapy on the pathological pattern of free amino acids and protein fractions in serum. Excerpta med. Intern. Congr. Ser. 74, 177 (1964).Google Scholar
  125. Dardenne, P., Cantala, P.: Le traitement de l’involution sénile par un Stéroide anabolisant (oenanthate de méthénolone). Toulouse méd. 65, 787–796 (1964).PubMedGoogle Scholar
  126. Dardenne, U.: Die Therapie der Retinopathia diabetica. Arzneimittel-Forsch. 9, 672 (1959).Google Scholar
  127. Dardenne, U.: The therapeutic applications of anabolic steroids in ophthalmology. Acta en-docr. (Kbh). 63, 143–153 (1961).Google Scholar
  128. Darracott, J.: Treatment of the painful knee fulfilling diagnostic criteria for “chondromalacia patellae”. Curr. med. Res. Opin. 1, 412–420 (1973).PubMedGoogle Scholar
  129. Davidson, J.F., Lochhead, M., McDonald, G.A., McNicol, G.P.: Fibrinolytic enhancement by stanozolol: a double blind trial. Brit. J. Haemat. 22, 543–559 (1972a).PubMedGoogle Scholar
  130. Davidson, J.F., McDonald, G.A., Conkie, J.A.: Fibrinolytic enhancement by stanozolol—a two year study. Brit. J. Haemat. 22, 639–640 (1972b).PubMedGoogle Scholar
  131. Davila Flores, O.E., Herrera, H., Ortega, R.: Effecto anabólico protéinico del decanoato de norandrostenolona. Médico (Méx). 8, 17–19 (1964).Google Scholar
  132. Deineko, N.F., Shustval, N.F., Ikhnenko, R.I., Bakumenko, I.S.: Treatment of peptic ulcer with anabolic hormones. Klin. Med. (Moskau) 51, 57–63 (1973).Google Scholar
  133. Delaney, T.J., Black, M.M.: Effect of fibrinolytic treatment in malignant atrophic papulosis. Brit. med. J. 1975III, 415.Google Scholar
  134. Delmont, J.: Non-tropical sprue. Modern concepts in connection with five cases. Thesis, Marseille, 1961.Google Scholar
  135. Demeulenaere, L.: Erfahrungen mit Methenolon bei Leberzirrhose und chronischer Hepatitis. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  136. Derot, M., Bernier, J.J.: “Anuric nephritis”: Treatment of nephropathies with testosterone propionate. Letter to Editor. J. Amer. med. Ass. 145, 47 (1951).Google Scholar
  137. Deutsch, M., Saxena, B.M., Lehmann, H.E.: Combined administration of thioridazine and fluoxymesterone in the treatment of geriatric patients. Curr. ther. Res. 12, 805–809 (1970).PubMedGoogle Scholar
  138. Dieckhoff, J., Schneeweiss, B.: Der Einfluß von katabolen und anabolen Steroiden auf die Antikörperbildung. Dtsch. Gesundh.-Wes. 20, 189–194 (1965).Google Scholar
  139. Dittrich, H., Seifert, E.: Zur Anwendung anaboler Steroide bei Magenresezierten. Med. Klin. 59, 821–823 (1964).PubMedGoogle Scholar
  140. Doane, B.D., Fried, W., Schwartz, F.: Response of uremic patients to nandrolone decanoate. Arch. intern. Med. 135, 972–975 (1975).PubMedGoogle Scholar
  141. Dodman, B., Cunliffe, W.J., Roberts, B.E., Sibbald, R.: Clinical and laboratory double-blind investigations on effect of fibrinolytic therapy in patients with cutaneous vasculitis. Brit. med. J. 1973II, 82–84.Google Scholar
  142. Dontas, S., Papanicolaou, N.T., Papanayiotou, P., Malamos, B.K.: Long-term effects of anabolic steroids on renal functions in the aged subject. J. Geront. 22, No. 3, 268–273 (1967). Dorn, W.: Landarzt 39, 4 (1963).PubMedGoogle Scholar
  143. Dowben, R.M.: Prolonged survival of dystrophic mice treated with 17α-ethyl-19-nortesto-sterone. Nature (Lond.) 184, Suppl. 25, 1966 (1959).Google Scholar
  144. Dowben, R. M.: Muscular dystrophy. Paper read at a Symposium on Anabolic Therapy, Detroit, Michigan, March 1962.Google Scholar
  145. Dowben, R.M.: Treatment of muscular dystrophy with steroids. New Engl. J. Med. 268, 912 (1963).Google Scholar
  146. Dowben, R.M.: Anabole Steroide bei Myopathien. Myopathien. Stuttgart: Georg Thieme Verlag, 1965.Google Scholar
  147. Dowben, R.M., Perlstein, M.A.: Muscular dystrophy treated with norethandrolone. Arch. intern. Med. 107, 245–251 (1961).PubMedGoogle Scholar
  148. Dowben, R.M., Vawter, G.F., Brandfonbrenner, A., Sniderman, S.P., Kaegy, R.D.: Polymyositis and other diseases resembling muscular dystrophy. Arch. intern. Med. 115, 584–594 (1965).PubMedGoogle Scholar
  149. Doyle, A.E., Pinkus, N.B., Green, J.: The use of oxandrolone in hyperlipidaemia. Med. J. Aust. 1, 127–129 (1974).PubMedGoogle Scholar
  150. Dresdale, F.C., Hayes, J.C.: Potential dangers in the combined use of methandrostenolone and sodium warfarin. J. med. Soc. N.J. 64, 609 (1967).PubMedGoogle Scholar
  151. Dubarry, J.J., Auche, Y., Bernard, J.-P., Fontanges, X.: Application thérapeutique des médications anabolisantes en gastro-enterologie à propos du Primobolan-dépôt. Gaz. méd. Fr. 72, 2896–2898 (1965).PubMedGoogle Scholar
  152. Dubarry, J.J., Tournerie, J., Marquier, A.: L’androgénothérapie dans le traitement des cirrhoses. Presse méd. 71, 1311–1313 (1963).Google Scholar
  153. Dubos, G., Hugonat, R.: Therapeutic trial. Strombaject in geriatrics. Lyon méd. 23, 183–186 (1974).Google Scholar
  154. Dudley, H.A.F., Robson, J.S., Smith, M., Stewart, C.P.: The permissive role of adrenal cortical hormones after injury in man. Metabolism 8, 895 (1959).PubMedGoogle Scholar
  155. Dutruel, R.: Sur trente cas de ‘grands vieillards’ malades chroniques traités par l’oxymétholone. Rev. franç. Géront. 11, 59–62 (1965).PubMedGoogle Scholar
  156. Dutz, H., Voigt, K., Wendler, J.: Über die Beeinflußbarkeit der experimentellen Ratten-Ne-phritis durch Testosteron, Oestradiol, Kastration und somatotropes Hormon. Z. ges. inn. Med. 11, 1115–1120 (1956).PubMedGoogle Scholar
  157. Eaton, J.C.: Metabolic effects in chronic renal failure. Proc. roy. Soc. Med. 52, 511–514 (1959).PubMedGoogle Scholar
  158. Eberhardt, G., Möhr, J., Oehlert, W., Schmidt, E., Schmidt, F.W., VondrÁŜek, P.: Kontrollierte Studie zur therapeutischen Wirkung von B-Vitaminen und einem anabolen Steroid bei chronischer Hepatitis. Dtsch. med. Wschr. 100, 2074–2082 (1975).PubMedGoogle Scholar
  159. Edwards, M.S., Curtis, J.R.: Decreased anticoagulant tolerance with oxymetholone. Lancet 1971II, 221. Google Scholar
  160. Efimov, A. S.: Efficacy and mechanism of action of anabolic steroids in diabetic angiopathy. Ter. Arkh. 42, 81–85 (1970).PubMedGoogle Scholar
  161. Efimov, A.S., Karabun, P.M.: Mechanism of action of anabolic steroids in the treatment of diabetes mellitus. Ter. Arkh. 44, 90–94 (1972).PubMedGoogle Scholar
  162. Eger, W.: Experimentelle Untersuchungen zur Frage der Leberschädigung und Oxymetholon im akuten und chronischen Versuch. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  163. Ehnholm, G., Huttunen, J.K., Kinnunen, P., Miettinen, T.A., Nikkila, E.A.: Effect of oxandrolone treatment on the activity of lipoprotein lipase, hepatic lipase and phospholipase A1 of human post-heparin plasma. New Engl. J. Med. 292, 1314–1317 (1975).PubMedGoogle Scholar
  164. Ehrlich, H.P., Hunt, T.K.: The effects of cortisone and anabolic steroids on the tensile strength of healing wounds. Ann. Surg. 170, 203–206 (1969).PubMedGoogle Scholar
  165. Ekert, H., Muntz, R.H., Colebatch, J.H.: Decreased anticoagulant tolerance with oxymetholone. Lancet 1971II, 609–610.Google Scholar
  166. Ekisenina, N.I., Krums, L.M., Lukash, L.K., Medvedeva, T.F., Taits, N.S., Fursova, G.A., Chanysheva, R.I.: Nerobol in a complex therapy of chronic enterocolitis. Sovetsk. Med. 35, 68–72 (1972).Google Scholar
  167. El-Abrashi, N., El-Danasonry, M.: Trial of anabolic agents in cases of chronic renal failure with uremia. J. Egypt. med. Ass. 44, 333–339 (1961).Google Scholar
  168. El-Mehairy, M.M., El-Tarabishi, N.: Study of the effect of combining anabolics with steroids in long-term therapy of bronchial asthma. J. Egypt. med. Ass. 43, 646–651 (1966).Google Scholar
  169. Endler, F.: Praktische Erfahrungen mit einem neuen anabolen Wirkstoff in der Orthopädie. Wien. klin. Wschr. 73, 481–485 (1961).PubMedGoogle Scholar
  170. Esposito, R., Pluvio, M., Giordano, D.: Anabolic agents in kidney disease: the effect of forme-bolone on protein synthesis in patients with renal insufficiency or nephrosis. Curr. Med. Res. Opin. 3, 43–45 (1975).PubMedGoogle Scholar
  171. Evans, J.T., Elias, E.G.: The erythropoietic response to anabolic therapy in patients receiving radiotherapy. J. clin. Pharmacol. 12, 101–104 (1972).Google Scholar
  172. Fabrykant, M.: Diabetic retinopathy: Preliminary report on the use of anabolic steroids and high-protein low-fat diets. J. Amer. Geriat. Soc. 10, 743–748 (1962).PubMedGoogle Scholar
  173. Fabrykant, M., Gelfand, M.L., Rosenberg, A.S.: Further experience with anabolic steroids in diabetic retinopathy: Factors precipitating retinal hemorrhages. Amer. J. med. Sci. 248, 304–316 (1964).PubMedGoogle Scholar
  174. Faergeman, O., Damgaard-Federsen, F.: Increase of post-heparin lipase activity by oxandrolone in familial hyperchylomicronemia. Scand. J. clin. Lab. Invest. 31, 27–31 (1973).PubMedGoogle Scholar
  175. Falkson, G., Falkson, H.C., Minnaar, P.C.: A clinical evaluation of stanozolol as an adjuvant to cytostatic treatment of cancer. S. Afr. Cancer Bull. 8, 54–62 (1964).Google Scholar
  176. Fallat, R.: Effects of anabolic and progestational agents upon triglycerides and triglyceride kinetics in normal and hyperlipemic patients. Lipids 9, 117–120 (1974).Google Scholar
  177. Fallat, R.W., Glueck, C.J.: Familial and acquired type V hyperlipoproteinemia. Atherosclerosis 23, 41–62 (1976).PubMedGoogle Scholar
  178. Falliers, C.J., Jorgensen, J.R., Tan, L.S., Bukantz, S.G.: Anabolic effects of stanozolol. Amer. J. Dis. Child. 106, 388–401 (1963).PubMedGoogle Scholar
  179. Fam, A.: The use of anabolizers in urology. J. Egypt. med. Ass. 46, 100–110 (1963).Google Scholar
  180. Fanfani, A., Ricca, M., Cherici, P.: Esperienze di terapia anabolizzante in vecchi TBC. G. Geront. 10, 659–671 (1962).Google Scholar
  181. Fantoli, U., Boccitto, G., Lorenzetti, L.: Azione del fenilpropionato di 19-nor-androstenolone sulla disprotidemia in soggetti affetti da tubercolosi polmonare. Ann. Ist. Forlanini 2, 218–237 (1959).Google Scholar
  182. Fastner, Z.: X. Intern. Congress of Gerontology, Jerusalem (1975). Fauchet, R.: Utilisation du stanozolol chez les malades immobilisés. Sem. Hôp. Paris 70–74 (1966).Google Scholar
  183. Fearnley, G.R.: Ethyloestrenol and postoperative venous thrombosis. Lancet 1973II, 95.Google Scholar
  184. Fearnley, G.R.: Fibrinolysis and deep-vein thrombosis. Lancet 1974I, 454–455.Google Scholar
  185. Fearnley, G.R., Chakrabarti, R.: Increase of blood fibrinolytic activity by testosterone. Lancet 1962II, 128.Google Scholar
  186. Fearnley, G.R., Chakrabarti, R.: Pharmacological enhancement of fibrinolytic activity of blood. J. clin. Path. 17, 328 (1964).PubMedGoogle Scholar
  187. Fearnley, G.R., Chakrabarti, R.: Oral fibrinolytic agents. Brit. med. J. 1968III, 498.Google Scholar
  188. Fearnley, G.R., Chakrabarti, R.: Phenformin and ethyloestrenol for Raynaud’s disease. Lancet 1969II, 1203.Google Scholar
  189. Fearnley, G.R., Chakrabarti, R., Evans, J.F.: Fibrinolytic treatment of rheumatoid arthritis with phenformin plus ethyloestrenol. Lancet 1966II, 757–761.Google Scholar
  190. Fearnley, G.R., Chakrabarti, R., Evans, J.F.: Effect of ethyloestrenol combined with phenformin or with metformin on platelet stickiness and serum-cholesterol in patients with occlusive vascular disease: Lancet 1968II, 1004–1007.Google Scholar
  191. Fearnley, G.R., Chakrabarti, R., Evans, J.F.: Fibrinolytic and defibrinating effect of phenformin plus ethyloestrenol in vivo. Lancet 1969I, 910–914.Google Scholar
  192. Fearnley, G.R., Chakrabarti, R., Evans, J.F.: Mode of action of phenformin plus ethylestrenol on fibrinolysis. Lancet 1971I, 723–725.Google Scholar
  193. Fearnley, G.R., Chakrabarti, R., Hocking, E.D., Evans, J.F.: Fibrinolytic effects of diguanides plus ethyloestrenol in occlusive vascular disease. Lancet 1967II, 1008–1011.Google Scholar
  194. Fenster, L.F.: The nonefficacy of short-term anabolic steroid therapy in alcoholic liver disease. Ann. intern. Med. 65, 738–744 (1966).Google Scholar
  195. Flegel, G.: Beeinflussung des Myocardstoffwechsels durch anabole Substanzen, ihre Verwertung in der Rehabilitationsbehandlung chronischer Herzmuskelschäden. Med. Klin. 57, 519–523 (1962a).Google Scholar
  196. Fiegel, G.: Die reparativen Eigenschaften anaboler Steroide am chronisch geschädigten Myokard. Wien. med. Wschr. 112, 951–954 (1962b).PubMedGoogle Scholar
  197. Fiegel, G., Bargheer, R.: Katamnestische Ergebnisse nach Behandlung Herzkranker mit ana-bolen Steroiden. Med. Klin. 61, 1870–1872 (1966).PubMedGoogle Scholar
  198. Fiegel, G., Bargheer, R., Kukwa, D.: Das Verhalten des Lipidstoffwechsels unter gleichzeitiger Gabe von Anabolika und essentiellen Phospholipiden. Arzneimittel-Forsch. 16, 443–446 (1966).Google Scholar
  199. Fiegel, G., Einfeldt, H.: Die reparativen Eigenschaften anaboler und androgener Steroide in der Rehabilitationsbehandlung von 2546 Herzkranken. Therapiewoche 21, 4042–4046 (1971).Google Scholar
  200. Fiegel, G., Fischer, E.K.: Antitoxisch-anabole Behandlung von Leberschäden. Ärztl. Prax. 11, 1526–1527 (1959).Google Scholar
  201. Fiegel, G., Kelling, H.-W.: Das Verhalten von Nor-Androstenolonphenylpropionat bei schweren Leberschädigungen. Vergleichende Untersuchungen zu früheren Ergebnissen mit Testo-steron-Propionat. Ärztl. Forsch. 13, I/158-I/161 (1959a).Google Scholar
  202. Fiegel, G., Kelling, H.-W.: Die Beeinflussung des schweren Leberparenchymschadens unter Zufuhr hochdosierter Androgenderivate und von Corticosteroiden. Ärztl. Forsch. 13, I/574–I/578 (1959b).Google Scholar
  203. Fiegel, G., Kukwa, D.: Experimentelle Studie über das Verhalten der Blutlipide während längerer Einwirkung verschiedener anaboler Steroide. Arzneimittel-Forsch. 18, 452–456 (1968).Google Scholar
  204. Figueroa, R.B.: Mesterolone in steatosis and cirrhosis of the liver. Acta hepato-gastroenterol. 20, 282–290 (1973).Google Scholar
  205. Fixson, U.: Methenolonoenanthat (Primobolan-Depot) in der postoperativen Behandlung. Med. Welt (Stuttg.) 19, 1109–1114 (1962).Google Scholar
  206. Fixson, U.: Einfluß von Anabolika auf den postoperativen Verlauf. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  207. Fixson, U.: Zur Wirkung von Anabolika auf den postoperativen Verlauf nach gynäkologischen Karzinomoperationen. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  208. Fölsch, E., Brügger, W., Immich, H.: Zur Beeinflussung der hämatotoxischen Effekte von Cy-clophosphamid durch das anabole Steroid Nortestosteronphenylpropionat. Verh. dtsch. Ges. inn. Med. 73. Kongreß 1967, München: J. F. Bergmann 1967.Google Scholar
  209. Fölsch, E., Brügger, E.W., Brands, W.: Zur Beeinflussung der hämotoxischen Effekte von Cyclophosphamide durch anabole Steroide. Arzneimittel-Forsch. 25, 59–66 (1975).Google Scholar
  210. Fontaine, M., Malmendier, C.L.: Carbohydrate content of human VLDL, IDL, LDL and HDL plasma apoproteins from fasting normal and hyperlipemic patients. Clin. chim. Acta 64, 91–93 (1975).PubMedGoogle Scholar
  211. Forsius, H.: The retinopathic initial symptoms of juvenile diabetes. Acta Ophthal. (Kbh.) 45, 255–256 (1967).Google Scholar
  212. Foss, G.L., Simpson, S.L.: Oral methyltestosterone and jaundice. Brit. med. J. 1959I, 259–263.Google Scholar
  213. Fossard, D.P., Field, E.S., Kakkar, V.V., Friend, J.R., Corrigan, T.P., Flute, P.T.: Fibrinolytic activity and postoperative deep-vein thrombosis. Lancet 1974I, 9–11.Google Scholar
  214. Fossati, C.: Anabolic steroids in the treatment of chronic pulmonary tuberculosis. Panminerva med. 5, 381–383 (1963).Google Scholar
  215. Fossati, C.: Sull’impiego degli steroidi anabolizzanti in terapia. Clin. ter. 70, 169–202 (1974).PubMedGoogle Scholar
  216. Fowler, W.M., Pearson, C.M., Egstrom, G.H., Gardner, G.W.: Ineffective treatment of muscular dystrophy with an anabolic steroid and other measures. New Engl. J. Med. 272, 875–882 (1965).Google Scholar
  217. Foz, M.: Esteroides anabolizantes. I—algunas consideraciones sobre esteroides anabolizantes. Ann. Med. (Med.) 50, 194–202 (1965).Google Scholar
  218. Franken, F.H., Dawecke, H., Gries, E.A., Schweinitz, H.A.v., Holzgrewe, H., Forstmann, U.: Langzeitbehandlung chronischer Lebererkrankungen mit Prednison und Me-thandrostenolon. Dtsch. med. Wschr. 88, 1979–1985 (1963).PubMedGoogle Scholar
  219. Freedman, P., Spencer, A.G.: Testosterone propionate in the treatment of renal failure. Clin. Sci. 16, 11 (1957).PubMedGoogle Scholar
  220. Fröhlich, R., Mumenthaler, M., Wiesendanger, M.: Ergebnisse der Anwendung von anabo-len Hormonen bei myatrophischen Erkrankungen. Praxis 51, 1296–1300 (1962).Google Scholar
  221. Furman, R.H., Howard, R.P., Berkowit, D.: Idiopathic hyperglyceridaemia treated with methyltestosterone and methandienone. Lancet 1963I, 837.Google Scholar
  222. Gabuzda, G.J., Jr., Eckhardt, R.D., Davidson, C.S.: Effect of choline and methionine, testosterone propionate and dietary protein on nitrogen balance in patients with liver disease. J. clin. Invest. 29, 566 (1950).PubMedGoogle Scholar
  223. Gaillard, L., Delphin, D., Ferrat, Y.: La méthode de Nasso: une méthode imprévue mais efficace de prophylaxie de la varicelle en collectivité d’enfants. Pédiatrie 22, 353–355 (1967).PubMedGoogle Scholar
  224. Gautier, E., Tönz, O.: Anaboles Hormon in der Behandlung der Anurie im Kindesalter. Helv. med. Acta 27, 535–538 (1960).PubMedGoogle Scholar
  225. Geoffroy, H., Coudoux, P., Maffioli, C., Chardon, P., Dalle, M.: Etude de l’effet thérapeutique d’un nouvel anabolisant: le bêta (p-hexyloxyphenyl) propionate de 19 nortestosterone, Anador. Gaz. méd. Fr., 77, 3842–3846 (1970).Google Scholar
  226. Gerber, W., Cottier, P.: Zur Wirkung anaboler Hormone auf die Azotämie bei Nierenversagen. Helv. med. Acta 28, 197–215 (1961).PubMedGoogle Scholar
  227. Gerok, W., Sickinger, S., Hennekeuser, H.H. (Hrsg.): Alkohol und Leber. Stuttgart-New York: Schattauer 1971.Google Scholar
  228. Gerritzen, F. M.: Diabetische retinopathie. Ned. T. Geneesk. 119, 964–969 (1975).Google Scholar
  229. Gessner, P.K., Gessner, T.: The interaction of barbital and testosterone relative to their hypnotic effects. Arch. int. Pharmacodyn. 201, 52–58 (1973).PubMedGoogle Scholar
  230. Geyer, G., Jesserer, H.: Kann der gesteigerte Eiweiß-Katabolismus während einer Cortisonthe-rapie durch anabole Steroide ausgeglichen werden? In: Die endokrine Behandlung des Mamma- und Prostatacarcinoms. Endokrine Regulationen des Kohlehydratstoffwechsels. Berlin-Göttingen-Heidelberg: Springer 1961.Google Scholar
  231. Geyer, G., Jesserer, H.: Ergebnisse und Probleme der Therapie mit eiweißanabolen Steroiden, diskutiert an Erfahrungen mit Methandrostenolon (Dianabol/Ciba). Dtsch. Arch. klin. Med. 208, 252–278 (1962).PubMedGoogle Scholar
  232. Gherondache, C.N., Dowling, W.J., Pincus, G.: Metabolic changes induced in elderly patients with an anabolic steroid oxandrolone. J. Geront. 22, 290 (1967).PubMedGoogle Scholar
  233. Ghione, M.: Anti-infective action of an anabolic steroid. Proc. Soc. exp. Biol. 97, 773–775 (1958).PubMedGoogle Scholar
  234. Gibba, A., Petterino, E.: Studio sull’azione renoprotettiva di un nuovo Steroide anabolizzante: il 19-nor-androstenolone decanoato. Minerva urol. 14, 3–15 (1962).Google Scholar
  235. Giles, A.R.: Fibrinolytic activity and deep-vein thrombosis. Lancet 1974I, 803.Google Scholar
  236. Gilliam, J.N., Herndon, H., Prystowsky, S.D.: Fibrinolytic therapy for vasculitis of atrophie blanche. Arch. Derm. Symp. (Chic.) 109, 664–667 (1974).Google Scholar
  237. Girolami, M.: La cirrosi del fegato può guarire clinicamente in una alta percentuale di casi con trattamento a base di testosterone e vitamina B1 ad alte dosi. Minerva med. 64, 1567–1623 (1973).PubMedGoogle Scholar
  238. Gjorup, S., Thaysen, J.H.: The effect of anabolic steroid (Durabolin) in the conservative management of acute renal failure. Acta med. scand. 167, 227–238 (1960).PubMedGoogle Scholar
  239. Glueck, C.J.: Progestins, anabolic-androgens, estrogens: effects on triglycerides and lipases. Clin. Res. 17, 475 (1971a).Google Scholar
  240. Glueck, C.J.: Effects of oxandrolone on plasma triglycerides and postheparin lipolytic activity in patients with types III, IV, and V familial hyperlipoproteinemia. Metabolism 20, 691–702 (1971b).PubMedGoogle Scholar
  241. Glueck, C.J., Fallat, R.W., Mendoza, S.: Effect of sex hormones on protamine inactivated and resistant post-heparin plasma lipases. Clin. Res. 23, 498A (1975).Google Scholar
  242. Glueck, C.J., Ford, S., Fallatt, R., Steiner, P.: Triglyceride removal efficiency and lipases: Effects of oxandrolone. Circulation 46, Suppl. II, 263 (1972).Google Scholar
  243. Glueck, C.J., Ford, S., Steiner, P., Fallat, R.: Triglyceride removal efficiency and lipoprotein lipases—effects of oxandrolone. Metabolism 22, 807 (1973).PubMedGoogle Scholar
  244. Glueck, C.J., Steiner, P., Swanson, P.: Amelioration of endogenous hyperglyceridemia by nor-ethindrone acetate and oxandrolone. Clin. Res. 18, 454 (1970a).Google Scholar
  245. Glueck, C.J., Swanson, F., Hutsell, T.: Effects of oxandrolone and norethindrone acetate on tissue and plasma lipases, and triglycerides. Circulation 42, Suppl. 3, 158 (1970b).Google Scholar
  246. Glueck, H.I., Glueck, C.J.: Clotting mechanism in patients with hypertriglyceridemia during therapy with anabolic or progestational drugs. Clin. Res. 18, 611 (1970).Google Scholar
  247. Glueck, H.I., Glueck, C.J.: Clotting mechanism in patients with hypertriglyceridemia during therapy with anabolic or progestational drugs. Thrombos. Diathes. haemorrh. (Stuttg.) 29, 499–509 (1973).Google Scholar
  248. Goebel, F.-D.: Diabetes mellitus und Mikroangiopathie. Dtsch. med. Wschr. 100, 382–385 (1975).PubMedGoogle Scholar
  249. Gokhale, B.B., Kotnis, M.G., Kasabedar, P.V.: A preliminary note on anabolic therapy in leprosy. J. trop. Med. Hyg. 67, 284–285 (1964).PubMedGoogle Scholar
  250. Goldenberg, I.S., Sedransk, N., Volk, H., Segaloff, A., Kelley, R.M., Haines, C.R.: Combined androgen and antimetabolite therapy of advanced female breast cancer. Cancer 36, 308–310 (1975).PubMedGoogle Scholar
  251. Goldman, A.G., Zarday, Z.: Effects of oxandrolone in advanced renal insufficiency. N.Y. St. J. Med. 73, 316–319 (1973).Google Scholar
  252. Goldstein, J., Combes, B.: The effect of steroids on the activity of the enzyme that catalyzes sulfobromophthalein-glutathione conjugation. J. Lab. clin. Med. 67, 830–835 (1966).PubMedGoogle Scholar
  253. Gomes, J.M.P., Lagreca, J.R., Moraes, C.R.: Emprêgo de anabolisante em cirurgia cardiaca. Hospital (Rio de J.) 78, 139–145 (1970).Google Scholar
  254. Gonnard, P., Lefranc, G., Gosse, R., Paris, E.: Recherches sur les propriétés protéino-anaboli-santes de l’androstanolone base. Sem. Hôp. Paris 33, 1 (1957).Google Scholar
  255. Goodman, J., Bessman, A.N.: Effect of nortestosterone decanoate on red cell 2, 3 diphosphogly-cerate and hematocrit in hemodialysis patients. Clin. Pharmacol. Ther. 17, 167–170 (1975).PubMedGoogle Scholar
  256. Gorokhovsky, B.I., Kitaeva, I.T.: The use of anabolic hormones in myocardial infarction. Klin. Med. (Moskau) 48, 29–34 (1970).Google Scholar
  257. Gramsch, H.: Klinischer Beitrag über die Anwendung von Primobolan bei Hepatopathien. Med. Welt (Stuttg.) 1963IV, 212–214.Google Scholar
  258. Gramsch, H.: Beobachtungen über die orale Methenolontherapie bei Hepatopathien. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  259. Gribbin, H.R., Flavell Matts, S.G.: Mode of action and use of anabolic steroids. Brit. J. clin. Pract. 30, 3–5, 7–9 (1976).Google Scholar
  260. Grönberg, A., Svanteson, G.: Svenska Laekartidn. 48, 2005 (1951) cited in W. Nordlöw, A. GrÖnberg, G. Svanteson: Sexualhormonterapi vid retinopathia diabetica. Nord. Med. 49, 742–744 (1953).Google Scholar
  261. Grossman, J., Yalow, A.A.: Effects of anabolic steroids on albumin metabolism. J. clin. Endocr. 25, 698–707 (1965).PubMedGoogle Scholar
  262. Gudbjarnason, S., Fenton, J.C., Wolf, P.L., Bing, R.J.: Stimulation of reparative processes following experimental myocardial infarction. Arch. intern. Med. 118, 33–40 (1966).PubMedGoogle Scholar
  263. Gürtler, J.: Untersuchungen über die Möglichkeit der Steigerung des Körpergewichts mit Stromba. Praxis 52, 900–902 (1963).Google Scholar
  264. Haberler, H., Pateisky, K.: Dystrophia musculorum progressiva: Results of clinical and biochemical examinations in the course of treatment with an anabolic substance (norandrosten-olondecanoate). Excerpta med. Int. Congr. Ser. 38, 161–162 (1961).Google Scholar
  265. Hagenbuchner, K.: Über den Anwendungsbereich anabol wirksamer Steroide in der Neurologic. Wien. klin. Wschr. 74, 214–219 (1962).PubMedGoogle Scholar
  266. Haggenmüller, F.: Anabole Steroide bei Kindern mit nephrotischem Syndrom. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  267. Haggenmüller, F.: Wirkung der Anabolikumbehandlung bei einem Kind mit Debré-de Toni-Fanconi-Erkrankung und Zystin-Speicherkrankheit. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  268. Hamerski, W.: Durabolin in the treatment of diabetic proliferative angioretinopathy. Klin. oczna 44, 461–465 (1974).PubMedGoogle Scholar
  269. Hamilton, L.D., Bennett, J.L., Silver, J.: Nandrolone phenpropionate in the treatment of geriatric patients with chronic brain damage. J. Amer. Geriat. Soc. 12, 373–378 (1964).PubMedGoogle Scholar
  270. Hamilton, M.: Lectures on the Methodology of Clinical Research, 2nd Ed. Edinburgh-London: Churchill Livingstone 1974.Google Scholar
  271. Hammer, F.: Zur Behandlung von Altersherzerkrankungen mit anabolen Steroiden. Med. Welt. (Stuttg.) 17, (N.F.) 2814–2817 (1966).Google Scholar
  272. Hansten, Ph.D.: Drug Interactions, 2nd Ed. Philadelphia: Lea & Febiger 1973.Google Scholar
  273. Hantschmann, N., Matzelt, D., Mertens, H.G., Nowakowski, H.: Zur Behandlung von Muskelkrankheiten mit anabolen Steroiden. Dtsch. med. Wschr. 87, 2619–2634 (1962).PubMedGoogle Scholar
  274. Harn, C.S.: Clinical experiences with Winstrol. M.D. Journal 12, 154–161 (1963).Google Scholar
  275. Harris, E.L., Fitzgerald, J.D.: The Principles and Practice of Clinical Trials. Edinburgh-London: E. & S. Livingstone 1970.Google Scholar
  276. Hartenbach, W.: Indikationen und Kontraindikationen für die Anwendung kataboler und ana-boler Hormone in der Chirurgie. Münch. med. Wschr. 104, 1567–1574 (1962).PubMedGoogle Scholar
  277. Haslock, D.I., Wright, V.: A corticosteroid-sparing agent in rheumatoid arthritis. A trial of nandrolone decanoate (Deca-Durabolin). Clin. Trials J. 4, 31–34 (1971).Google Scholar
  278. Hecht, Y.: Traitement de l’insuffisance hépatocellulaire des cirrhoses par les anabolisants. Rev. franç. Gastro-Entérol. 65, 51–61 (1971).Google Scholar
  279. Hedner, U., Nilsson, I.M., Isacson, S.: Phenformin and ethyloestrenol in recurrent deep venous thrombosis. Presented at 10. Erfurter Konferenz über Hämostase und Thrombose, Mai 1975. Folia haemat. (Lpz.) In press. (1975a).Google Scholar
  280. Hedner, U., Nilsson, I.M., Isacson, S.: Effect of ethyloestrenol on fibrinolysis in the vessel wall. Thrombos. Diathes. haemorrh. (Stuttg.) 34, 609 (1975b).Google Scholar
  281. Hellmann, L., Bradlow, H.L., Zumoff, B., Fukushima, D.K., Gallagher, T.F.: Thyroid-an-drogen interrelations and the hypocholesteremic effect of androsterone. J. clin. Endocr. 19, 936 (1959).Google Scholar
  282. Hendler, E.D., Goffinet, J.A., Ross, S., Longnecker, R.E., Bakovic, V.: Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis. New Engl. J. Med. 291, 1046–1051 (1974).PubMedGoogle Scholar
  283. Henkes, H.E., Riaskoff, S., Houtsmuller, A.J.: Nieuwe ontwikkelingen in de behandeling van de diabetische retinopathie. Ned. T. Geneesk. 115, 1765–1769 (1971).PubMedGoogle Scholar
  284. Herk, E.J., van: An investigation of the effect of the steroid ethylestrenol on facial hairgrowth. Acta endocr. 41, 407–410 (1962).PubMedGoogle Scholar
  285. Herrmann, J.B., Woodward, S.C.: An experimental study of wound healing accelerators. Amer. Surg. 38, 26–34 (1972).Google Scholar
  286. Heyck, H., Laudahn, G., Lüders, C.J., Müller-Stephann, H., Schmidt-Peter, P.: Anabolic steroids and digitoxin in the treatment of progressive muscular dystrophy. Acta paediat. scand. 54, 205–217 (1965).PubMedGoogle Scholar
  287. Hiekkala, H.: The influence of anabolic hormones on retinopathy in juvenile diabetics. Diabetologia 1, 134 (1965).Google Scholar
  288. Hirayama, C., Kimura, N., Masuya, T.: Anabolic steroid effect on hepatic protein synthesis in patients with liver cirrhosis. Digestion 3, 41–47 (1970).PubMedGoogle Scholar
  289. Hock, C.W.: Medical treatment of the functionally ill geriatric patient. Geriatrics 16, 182–184 (1961).PubMedGoogle Scholar
  290. Hofmann, H., Zeppek, E.: Über die Behandlung der Retinopathia diabetica mit einem anabolen Steroid. Klin. Mbl. Augenheilk. 143, 821–832 (1963).Google Scholar
  291. Honegger, H., Bohleber, U.: Klinik und Therapie der Retinopathia diabetica. Med. Mschr. 25, 298–308 (1971).PubMedGoogle Scholar
  292. Horky, J.: The use of anabolic steroids in the treatment of liver diseases. T. Gastroent. 10, 109–126 (1967).PubMedGoogle Scholar
  293. Horn, Y.: Leucopoietic properties of four different androgenic hormones in irradiated rats. Scand. J. Haemat. 8, 470–475 (1971).Google Scholar
  294. Houtsmuller, A.J.: The therapeutic applications of anabolic steroids in ophthalmology: biochemical results. Acta endocr. (Kbh.) Suppl. 63, 154–169 (1961).Google Scholar
  295. Houtsmuller, A.J.: Influence of deca-durabolin on the usual course of the glucose tolerance test in diabetes. Diabetologia 1, 80 (1965).Google Scholar
  296. Houtsmuller, A.J., Henkes, H.E.: Klinische und biochemische Effekte von Nandrolon phenyl-propionat (Durabolin) und Nandrolondecanoat (Deca-Durabolin) bei diabetischer Retinopathie. Ber. dtsch. Ophthal. Ges. 63, 57–62 (1960).Google Scholar
  297. Houtsmuller, A.J., Henkes, H.E.: Clinical investigations of patients with diabetic retinopathy treated with anabolic steroids. Paper presented at the Vth Congress of the International Diabetes Federation, Toronto, July, 1964.Google Scholar
  298. Houtsmuller, A.J., Henkes, H.E., van Poppel, A.L.A.: Clinical investigation of patients with diabetic retinopathy treated with anabolic steroids. Paper read at the Joint Congress Irish Ophthalmological Society—British Diabetic Society, Dublin, April 1963.Google Scholar
  299. Houtsmuller, A.J., van Poppel, A.L.A.: Treatment of diabetic retinopathy with anabolic steroids. Ophthalmologica (Basel) 145, 185–206 (1963).Google Scholar
  300. Huber, E.G.: Therapeutische Erfahrungen mit anabolen Hormonen. Münch. med. Wschr. 103, 1133 (1961).Google Scholar
  301. Huguet, F.-J.-D., Tournigand, P., Duran, G.: Effets de l’androstanolone-base sur 120mala-des. Presse méd. 69, 2433–2434 (1961).PubMedGoogle Scholar
  302. Hunter, P.R., Cotton, S.G., Kelsey, J.H., Blooms, A.: Controlled trial of methandienone in treatment of diabetic retinopathy. Brit. med. J. 1967III, 651–653.Google Scholar
  303. Huseman, C., Johanson, A.: Growth hormone deficiency in anorexia nervosa. J. Pediat. 87, 946–948 (1975).PubMedGoogle Scholar
  304. Hussar, D.A.: Drug interactions. Amer. J. Pharm. 145, 65–116 (1973).PubMedGoogle Scholar
  305. Hvidberg, E.F., Dayton, P.G., Read, J.M., Wilson, C.H.: Studies of the interaction of phenylbutazone, oxyphenbutazone, and methandrostenolone in man. Proc. Soc. exp. Biol. (N.Y.) 129, 438–443 (1968).Google Scholar
  306. Igari, J., Hayashi, Y., Ushio, M., Miki, S., Iwado, M.: The effect of long-term administration of anabolic steroid upon total serum cholesterol level. Jap. J. Geriat. 3–4, 275–282 (1966).Google Scholar
  307. Igic, R., Jelicic, J., Nikulin, E., Stern, P.: Myotrophischer Effekt des Metenolazetat auf die experimentelle Muskeldystrophie der Ratte. Endokrinologie 54, 103–106 (1969).PubMedGoogle Scholar
  308. Iisalo, E., Kasanen, A., Karki, N., Tala, E.: The effect of an anabolic steroid, nor-testosterone phenyl propionate (durabolin), on the urinary and plasma steroids in patients with normal and decreased renal function. Acta med. scand. (Kbh.) 171, 183–186 (1962).Google Scholar
  309. Iovine, G., Gierson, H.W.: Methandrostenolone as an anabolic agent in emphysema. Curr. ther. Res. 5, 219–231 (1963).PubMedGoogle Scholar
  310. Isacson, S., Nilsson, I.M.: Effect of treatment with combined phenformin and ethyloestrenol on the coagulation and fibrinolytic systems. Scand. J. Haemat. 7, 404–408 (1970).PubMedGoogle Scholar
  311. Jaffe, M.D.: Ethylestrenol, coronary artery disease and collaterals. Clin. Res. 21, 813 (1973).Google Scholar
  312. Jaffe, M.D.: Improvement in postexercise “ischemic” electrocardiographic changes by testosterone cypionate treatment. Clin. Res. 22, No. 4, 595A (1974).Google Scholar
  313. James, V.H.T., Landon, J., Wynn, V.: Effect of an anabolic steroid (methandienone) on the metabolism of Cortisol in the human. J. endocr. (Kbh.) 25, 211–220 (1962).Google Scholar
  314. Jannuzzi, C., Bassetti, D., Frigerio, G.: Ricerche cliniche controllate sull’effetto di steroidi ana-bolizzanti nell’epatite virale. Minerva med. 61, 1902–1911 (1970).PubMedGoogle Scholar
  315. Japa, J., Narbutt, B., Hankiewicz, J., Stas, J.: The influence of encorton and of dianabol administration on protein metabolism in Addison’s disease. Endokr. pol. 17, 1–10 (1966).PubMedGoogle Scholar
  316. Jefimov, A.S.: Die Behandlung der diabetischen Angiopathien. IV. Internationales Donau-Sym-posium über Diabetes mellitus, Dubrovnik, Abstract 133 (1975).Google Scholar
  317. Johnston, I.D.A., Burn, J.I.: The effect of nandrolone (durabolin) on the white cell counts of rats treated with chlorambucil. Paper read at a Symposium at the University Dept. of Surgery, Royal Infirmary, Sheffield, Nov. 1966.Google Scholar
  318. Johnson, P.C., Jr.: Weight gain in geriatric patients. Paper presented at a Symposium on Anabolic Therapy, Detroit, Michigan, March 1962.Google Scholar
  319. Johnson, R.H., McLellan, D.L.: Multiple sclerosis. Practitioner 209, 183–190 (1972).PubMedGoogle Scholar
  320. Jones, C.R., van Itallie, T.B., Stevenson, S.S., Pigman, W.W.: Decrease in hydroxyproline excretion in a patient with Marfan’s syndrome after methandrostenolone therapy. J. Amer. med. Ass. 207, 2085–2086 (1969).Google Scholar
  321. Jose, A.D., Mitchell, A. S.: Elevation of serum cholesterol by an anabolic steroid. Lancet 1964I, 473–474.Google Scholar
  322. Jungck, E.C., Greenblatt, R.B.: Methandrostenolone, an oral anabolic agent. Sth. med. J. (Bgham, Ala.) 57, 909–913 (1964).Google Scholar
  323. Kaeser, H.E.: Zur Frage der Behandlung der Myopathien mit Sexualhormonen und ihren Deri-vaten. Nervenarzt 32, 38–40 (1961).PubMedGoogle Scholar
  324. Kahn, S.B., Conroy, J.F., Brodsky, I.: Effect of nandrolone phenpropionate on myelopoiesis. J. med. exp. Clin. 5, 303–309 (1974).Google Scholar
  325. Kaiser, H.: Cortisonderivate in Klinik und Praxis. 6th Ed., Stuttgart: Thieme 1973.Google Scholar
  326. Kalliomäki, J.L., Markkanen, T.K., Pirila, A.M., Ruikka, I.: Norandrostenolone decanoate— a new anabolic steroid with prolonged effect. Ann. med. intern. fenn. 50, 178–184 (1961a).Google Scholar
  327. Kalliomäki, J.L., Pirilä, A.M., Ruikka, I.: A therapeutic trial with ethyl-estrenol in geriatric patients. Acta endocr. (Kbh.) Suppl. 63, 124–128 (1961b).Google Scholar
  328. Kalliomäki, J.L., Seppälä, P.: Norandrostenolone decanoate as a cardiac anabolizer studied by means of electrocardiographic changes. Cardiologia 43, 124–128 (1963).Google Scholar
  329. Karjala, R.J., Ford, R.V.: Prolonged anticatabolic activity of nandrolone decanoate during corticosteroid therapy. Geriatrics 19, 511–516 (1964).PubMedGoogle Scholar
  330. Kasich, A.M.: Clinical evaluation of nandrolone phenpropionate in patients with gastrointestinal disease. Amer. J. Gastroent. 40, 628–633 (1963).PubMedGoogle Scholar
  331. Kerreijn, K.F., Delver, A.: Ethylestrenol (Orgabolin): Effects on asthmatic children during corticosteroid treatment. Scand. J. Resp. Dis. Suppl. 68, 70–77 (1969).Google Scholar
  332. Kessel, M.: Untersuchungen über den Einfluß anaboler Substanzen auf die Stickstoff-Retention bei akutem Nierenversagen. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  333. Kill, J.M.: Behandlung einer an Brustkrebs Erkrankten mit Endoxan und anabolem Hormon. Erfahrungsbericht. Münch. med. Wschr. 103, 1767–1768 (1961).PubMedGoogle Scholar
  334. Kink, R.: Über die Wirkung anaboler Steroide beim Diabetes mellitus. Med. Mschr. 16, 463–467 (1962).PubMedGoogle Scholar
  335. Kirk, J., Handley, D.A.: Experiences in the use of fibrinolytic agents in Behçet’s syndrome. Aust. J. Derm. 13, 5–10 (1972).Google Scholar
  336. Kleibel, F.: Die Wirkungen von Androstan-17β-ol-3-on auf den Stoffwechsel Karzinomkranker während der Strahlenbehandlung. Strahlentherapie 118, 446–453 (1962a).PubMedGoogle Scholar
  337. Kleibel, F.: Die anabole Wirkung von Norsteroiden und Ethylestrenol in der Strahlenbehandlung. Munch. med. Wschr. 104, 2514–2518 (1962b).PubMedGoogle Scholar
  338. Kleibel, F.: Die Behandlung kataboler Zustände in der Radiologic Med. Welt 47, 2529 (1962c).Google Scholar
  339. Kleibel, F.: Wirkung von Anabolika auf den Stoffwechsel Tumorkranker während der Strahlentherapie. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964a.Google Scholar
  340. Kleibel, F.: Klinische Veränderungen am Eiweiß-, Stickstoff-, Nukleoproteid-, Purin-, Phosphor-, Elektrolyt-und Wasserhaushalt während der Strahlentherapie. In: Einführung in die klinisch-experimentelle Radiologic. München-Berlin: Urban & Schwarzenberg 1964b.Google Scholar
  341. Kleibel, F.: Langwirkendes Anabolikum (Clinibolin) als Adjuvans in der Tumortherapie. Münch. med. Wschr. 111, 2452–2454 (1969).PubMedGoogle Scholar
  342. Kleibel, F.: Klinische Ergebnisse der Kombinationsbehandlung von 32Phosphor und Anabolika bei multiplen Knochenmetastasen. Fortschr. Röntgenstr. 116, 66–67 (1972).Google Scholar
  343. Kliaczko, W.R., Tirkina, T.N., Michajlowa, I.N.A.: Diabetic retinopathy and its complex treatment with particular reference to therapy with anabolic steroids. Endokr. pol. 21, 383–392 (1970).PubMedGoogle Scholar
  344. Kluthe, R.: Die N-Bilanz bei nephrotischem Syndrom unter verschiedenen Steroiden. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  345. Kluthe, R., Lampe, J.: Experimenteller Beitrag zur Strahlentherapie der Ratten-Masugi-Ne-phrose. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  346. Klyachko, V.R., Tirkina, T.N., Ryabchuk, O.G., Mazovetsky, A.G.: Treatment of diabetic retinopathies. Probl. Endokr. 17, 25–30 (1971).Google Scholar
  347. Kochakian, C.D.: A comparison of the renotrophic with the androgenic activities of various steroids. Amer. J. Physiol. 142, 315–325 (1944).Google Scholar
  348. König, H.: Behandlung der Retinopathia diabetica. Dtsch. med. Wschr. 97, 1196 (1972).Google Scholar
  349. Kolodny, A.L.: Methandrostenolone (Dianabol) in the clinical management of weight deficit. Med. Tms (N.Y.) 91, 9–19 (1963).Google Scholar
  350. Komarov, F.I., Lisovsky, V.A., Lisovsky, I.V., Schedrunov, V.V.: The effect of nerobol and aminocrovin on the free amino acids content in peptic ulcer. Sovetsk. Med. 36, 83–87 (1973).Google Scholar
  351. Konrad, R.M., Ammedick, U., Hupfauer, W., Ringler, W.: Der Effekt anaboler Steroide auf die Stickstoffbilanz bei Patienten nach Lungenoperationen. Chirurg 38, 168–171 (1967).PubMedGoogle Scholar
  352. Kopera, H.: Über therapeutische Versuche mit anabolen Steroiden bei diabetischer Retinopa-thie. Abhandl. dtsch. Akad. Wiss. Berlin Kl. Med. 3, 361–404 (1964).Google Scholar
  353. Kopera, H.: Clinical Experiences with Anabolic Steroids in some Special Indications. Hormonal Steroids, Biochemistry, Pharmacology and Therapeutics, Vol.2, pp.195–200. New York: Academic Press 1965.Google Scholar
  354. Korst, D.R., Bowers, C.Y., Flokstra, J.H., McMahon, F.G.: Clinical evaluation of a new anabolic agent 7α, 17α-dimethyltestosterone (bolasterone). Clin. Pharmacol. Ther. 4, 734–739 (1963).PubMedGoogle Scholar
  355. Kracht, J.: Anabole Hormone und sekundäre Nebennierenrindenatrophie. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  356. Kral, V.A., Wigdor, B.T.: Androgen effect on senescent memory function. Geriatrics 14, 450–456 (1959).Google Scholar
  357. Krizek, V., Stepanek, P., Sadilek, L.: Starvation and anabolic steroids. Metab. Clin. Exp. 18, 585–592 (1969).PubMedGoogle Scholar
  358. Kroath, F.: Zur Behandlung der Presbyakusis mit Sexualhormonen. Z. Laryng. Rhinol. 46, 552–555 (1967).Google Scholar
  359. Krotov, V.P.: The effect of anabolic steroids on the course of uremia. Bull. exp. biol. Med. 62, 34–37 (1966).Google Scholar
  360. Kruskemper, H.-L.: Anabolic Steroids. New York-London: Academic Press 1968.Google Scholar
  361. Kruskemper, H.-L.: Androgene, anabole Steroide und Fettstoffwechsel. Z. Ernährungsw. Suppl. 12, 16–21 (1972).Google Scholar
  362. Kruskemper, H.-L., Reichertz, P.: Der Einfluß eines anabol wirksamen Steroids (1-Methyl-17β-hydroxy-5a-androst-l-en-3-on) auf Veränderungen des Elektrokardiogramms bei experi-menteller Hyperthyreose. Z. ges. exp. Med. 137, 85 (1963).Google Scholar
  363. Krums, L.M.: Dynamic changes of some protein metabolism indices in patients with chronic enterocolitis against the background of nerobol medication. Vop. Pitan. 30, 44–46 (1971).PubMedGoogle Scholar
  364. Küchle, H. J.: Diabetes und Auge. Med. Welt 18, 1985–1988 (1967).Google Scholar
  365. KÜhn, W.: Über die Wirkung einer neuartigen anabol wirksamen Substanz (1-Methyl-Δ 1-an-drostenolönanthat) auf die Ernährungsverhältnisse bzw. den Verlauf tuberkulöser Lungener-krankungen. Dissertation, Med. Akad. Düsseldorf 1964.Google Scholar
  366. Kuemmerle, H.P., Garrett, E.R., Spitzy, K.H.: Klinische Pharmakologie und Pharmakothera-pie. 3rd ed., München-Berlin-Wien: Urban & Schwarzenberg 1976.Google Scholar
  367. Kuhn, E.: Progressive Muskeldystrophie, Myotome, Myasthenic: Gespräch über die Therapie der progressiven Muskeldystrophie (Gesprächsleitung: R.Beckmann), pp.145–155. Berlin-Heidelberg-New York: Springer 1966.Google Scholar
  368. Kulcsar-Gergely, J., Kulcsar, A., Kiss, A.: The role of sex differences in the effect of anabolics on the liver. Arzneimittel-Forsch. 25, 417–420 (1975).Google Scholar
  369. Kuo, P.T., Quick, R.E.: Improvement of hypertriglyceridemia by anabolic agent in primary type I hyperlipoproteinemia. Circulation 42, Suppl. 3, 18 (1970).Google Scholar
  370. Kutschera, E.: Probleme der diabetischen Retinopathie. Wien. klin. Wschr. 82, 706–710 (1970).PubMedGoogle Scholar
  371. Kutschera-Aichbergen, H.: Anabolika bei biochemischen Myokardschäden. Wien. med. Wschr. 116, 352–354 (1966).PubMedGoogle Scholar
  372. Kutzsche, A.: Experimentelle Beeinflussung von Tierinfektionen durch Methenolonester. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  373. Kuzell, W.C.: Methandrostenolone in rheumatic diseases and osteoporosis. Geriatrics 17, 428–441 (1962).PubMedGoogle Scholar
  374. Lachnit, K.S., Zwerina, R.: Zur Frage der Anwendung anaboler Steroide in der Geriatric Münch. med. Wschr. 107, 1125–1128 (1965).PubMedGoogle Scholar
  375. Lampitella, P.: Gli steroidi anabolici nel trattamento dell’ulcera sperimentale alla Shay. Boll. Soc. ital. Biol. sper. 40, 1584–1587 (1964).PubMedGoogle Scholar
  376. Lancet Editorial: Lipid-lowering drugs after myocardial infarction. Lancet 1975I, 501–502.Google Scholar
  377. Landon, J., Wynn, V., Samols, E.: The effect of anabolic steroids on blood sugar and plasma insulin levels in man. Metabolism 12, 924 (1965).Google Scholar
  378. Langnickel, D.: Zur Behandlung von Malignomen mit Tris-Äthyleniminobenzochinon, 19-Norandrostenolon-Decanoat und Prednison. Med. Welt 18, 1015–1022 (1963).PubMedGoogle Scholar
  379. Langsch, H.-G.: Zur Frage der Beeinflussung des Kohlehydratstoffwechsels bei Diabetikern durch Oral-Turinabol. Medicamentum 11, 106–107 (1970).Google Scholar
  380. Laurence, D.R.: Clinical Pharmacology. 4th Ed. Edinburgh-London: Churchill Livingstone 1973.Google Scholar
  381. Laurijssens, M., Vuylsteek, K., Vermeulen, A.: Progressive myopathische dystrofie. Belg. T. Geneesk. 16, 774–784 (1960).PubMedGoogle Scholar
  382. LeBeau, R.J., Robinson, R.W.: Effect of an anabolic steroid on hyperlipemia. Cardiovasc. Res. VI. World Congr. Cardiol. 196 (1970).Google Scholar
  383. Leevy, C.M.: Fatty liver: A study of 270 patients with biopsy proven fatty liver and a review of the literature. Medicine (Balt.) 41, 249 (1962).Google Scholar
  384. Leevy, C.M.: Abnormalities of hepatic DNA synthesis in man. Medicine 45, 423–433 (1966).PubMedGoogle Scholar
  385. Leevy, C.M.: Clinical diagnosis, evaluation and treatment of liver disease in alcoholics. Fed. Proc. 26, 5, 1474–1481 (1967).PubMedGoogle Scholar
  386. Leevy, C.M.: Cirrhosis in alcoholics. Med. Clin. N. Amer. 52, 6, 1445–1455 (1968).PubMedGoogle Scholar
  387. Leevy, C.M.: Therapie der Alkoholfettleber und Hepatitis. Therapiewoche 20, 2396–2398 (1970).Google Scholar
  388. Lefrançois, J.-J.: De l’emploi d’un stéroide anabolisant en milieu neuro-psychiatrique. Rev. Neuropsichiat. Ouest 12, 17–27 (1966).Google Scholar
  389. Leschinsky, L.A., Kharitonova, V.V.: Experience in the therapeutic employment of nerobol in combination with potassium salts in patients with the syndrome of chronic coronary insufficiency. Klin. Med. 48, 38–42 (1970).Google Scholar
  390. Leschinsky, L.A., Kharitonova, V.V.: Combined therapy with nerobol and potassium salts in ischemic disease of the heart. Terap. Arkh. 44, 40–44 (1972).Google Scholar
  391. Leschinsky, L.A., Pevchikh, V.V., Petrov, N.M.: The use of methylandrostendiol in myocardial dystrophies and atherosclerotic cardiosclerosis. Ter. Arkh. 39, 84–87 (1967).Google Scholar
  392. Leschinsky, L.A., Pevchikh, V.V., Trusov, V.V., Vakhrushev, Y.M., Verevkin, A.M.: Comparative investigation into the effectiveness of nerobol and quateron as well as their combinations in gastric and duodenal ulcers. Klin. Med. (Moskau) 50, 68–73 (1972).Google Scholar
  393. Leyritz, M.J., Capron, C., Capron, H., Sanchez, F., Timsit, M.: Action favorable du P.P.N.A. chez les malades atteintes de démence de la sénilité. Ann. méd.-psychol. 5, 1–3 (1961).Google Scholar
  394. Lindner, H.: Zum Verhalten von Bilirubin, alkalischer Phosphatase, Transaminasen (GOT und GPT) und des Bromsulfophthaleintestes bei Patienten mit Leberzirrhose und chronischer Hepatitis unter peroraler Primobolan-Therapie. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964a.Google Scholar
  395. Lindner, H.: Klinische Beobachtungen über Langzeitbehandlung mit Primobolan. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964b.Google Scholar
  396. Lindner, H.: Langzeittherapie der Leberzirrhose mit anabolen Steroiden. Med. Klin. 62, 59–64 (1967 a).Google Scholar
  397. Lindner, H.: Treatment of liver cirrhosis with anabolic steroids. Recent Advanc. Gastroenterol. 3, 662–664 (1967b).Google Scholar
  398. Linet, O.: Interactions between androgenic-anabolic steroids and glucocorticoids. Fortschr. Arz-neimittel-Forsch. 14, 139–195 (1970).Google Scholar
  399. Lineva, V.A.: On the correcting effect of anabolic preparations on the protein composition of the blood in patients with acute coronary insufficiency. Kardiologija 11, 75–78 (1971).Google Scholar
  400. Liotta, S., Scandariato, V., de Laurenzi, A.: Influenza del prednisone e degli steroidi anaboliz-zanti sulla risposta anticorpale ad antigeni stafilococcici. Progr. med. 23, 432–435 (1967).Google Scholar
  401. Little, P.J., Bailey, R.R.: Effect of tetracyclines on level of blood urea in patients with renal failure. Aust. Ann. Med. 19, 88 (1970).Google Scholar
  402. Littmann, L.: Changes of glucose tolerance and plasma immunoreactive insulin level before and after treatment of type IV and type V hyperlipoproteinemia with oxandrolone. Diabetologia 10, 396 (1974).Google Scholar
  403. Lods, J.-C.: Intérêt d’un nouvel anabolisant à action prolongée en gastro-entérologie. Gaz. méd. Fr. 71, 3338–3339 (1964).PubMedGoogle Scholar
  404. Loewit, K.: Über den Einfluß anaboler Hormone auf die Folgen einer Strahlenschädigung bei der weißen Maus. Strahlentherapie 125, 281–298 (1964).PubMedGoogle Scholar
  405. Lomazova, M.M.: Methyluracil and nerobolin in the antirecurrence treatment of patients with ulcer disease. Vrach. Delo 1, 56–57 (1973).PubMedGoogle Scholar
  406. Longridge, R.G.M., Gilliam, P.M.S., Barton, G.M.G.: Decreased anticoagulant tolerance with oxymetholone. Lancet 1971II, 90.Google Scholar
  407. Lorimier, A.A., de, Gordan, G.S., Lowe, R.C., Carbone, J.V.: Methyltestosterone, related steroids and liver function. Arch. intern. Med. 116, 289–294 (1965).Google Scholar
  408. Louyot, P., Gaucher, A., Benoit, P.: Etude clinique d’un nouvel anabolisant, le stanozolol. Ann. méd. Nancy 4, 203–211 (1965).Google Scholar
  409. Lundberg, P.O., Blom, S.: Behandling av muskeldystrofier med anabola steroider. Opusk. med. (Stockh.) 8, 125–129 (1963).Google Scholar
  410. MacMaster, D.R., Alamin, K.: Treatment of severe weight loss with methandrostenolone—a less virilizing anabolic agent. Amer. J. Psychiat. 120, 179–180 (1963).Google Scholar
  411. Maggi, C., Barbi, G.: Lo stato nutritionale proteico del bronchitico cronico. Arch. Sci. med. 110, 668 (1960).Google Scholar
  412. Makarov, G.A.: The mechanism of disturbances of synthetic processes in tissues in prolonged hypodynamia. Patol. Fiziol. Eksp. Ter. 4, 41–45 (1974).PubMedGoogle Scholar
  413. Mall, G., Heilbrunn, A., Paarmann, H.F., Junemann, H.J., Rheingans, W.R.: Die Behand-lung der multiplen Sklerose mit anabolen Steroiden. Med. Klin. 63, 2075–2077 (1968).PubMedGoogle Scholar
  414. Manai, G., Piccinini, G.: La metazina capronato (2-metil-5-androstan 17-ol-3, 3’-azina-17-cap-ronato) in terapia geriatrica. G. Geront. 19, 357–367 (1971).Google Scholar
  415. Mandal, B.K., McNulty, M.: Treatment of haemolytic-uraemic syndrome with phenformin and ethyloestrenol. Lancet 1971II, 1036.Google Scholar
  416. Markiewicz, K.: Durabolin in the management of nephrotic syndrome. Wiad. lek. 18, 661–664 (1965).PubMedGoogle Scholar
  417. Markov, M.I., Piralov, G.V.: Use of corticosteroids and anabolic steroids in the treatment of patients with liver cirrhosis. Vrach. Delo 4, 70–72 (1972).PubMedGoogle Scholar
  418. Marquier, A.: L’oxymetholone en geriatric Experience sur quarantecinq cas. Rev. franç. Géront. 10, 294–296 (1964).PubMedGoogle Scholar
  419. Martini, G.A., Strohmeyer, G., Dölle, W.: Was ist gesichert in der Therapie von Leberkran-ken? Internist 10, 456–464 (1969).PubMedGoogle Scholar
  420. Martins, J.K.: Corticosteroid side effects counteracted by anabolic therapy. Gen. Pract. Kansas 27, 6–9 (1964).Google Scholar
  421. Masson, G., Corcoran, A.C., Page, I.H.: Dietary and hormonal influences in experimental uremia. J. Lab. clin. Med. 34, 925–931 (1949).PubMedGoogle Scholar
  422. Matsumoto, S., Takabatake, Y., Seike, S.: Clinical and experimental study on the effect of protein anabolic hormone, deca-durabolin, on lesions of bones and joints. Excerpta med. (Sect. 3) 17, 536 (1963).Google Scholar
  423. Matzelt, D.: Beeinflussung von Serum-Enzymaktivitäten durch anabole Steroide bei muskel-kranken Patienten. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  424. Meerson, F.S.: Hyperfunktion, Hypertrophic und Insuffizienz des Herzens. Berlin: VEB Verlag Volk und Gesundheit 1969.Google Scholar
  425. Melmon, K.L., Morrelli, H.F.: Clinical Pharmacology. New York: MacMillan Company 1972.Google Scholar
  426. Mendenhall, C.L.: Augmented release of hepatic triglycerides with anabolic steroids in patients with fatty liver. Amer. J. dig. Dis. 19, 122–126 (1974).PubMedGoogle Scholar
  427. Menon, I.S.: Treatment of cutaneous vasculitis and recurrent superficial phlebitis and thromboembolism. Antiseptic 67, 776–780 (1970).Google Scholar
  428. Menon, I.S.: Metformin and stanozolol in blood fibrinolytic activity. Brit. med. J. 1971I, 289–290.Google Scholar
  429. Menon, I.S.: The role of phenformin and ethyloestrenol or stanozolol in the treatment of decreased fibrinolytic states. Acta Univ. Carol. (Med. Monogr.) 52, 19–23 (1972).Google Scholar
  430. Menon, I.S., Cunliffe, W.J.: Phenformin and ethyloestrenol for Raynaud’s disease. Lancet 1969II, 1135.Google Scholar
  431. Menon, I.S., Cunliffe, W.J., Dewar, H.A.: Preliminary report of beneficial effect of phenformin in combination with ethyloestrenol in treatment of cutaneous vasculitis and Behcet’s syndrome. Postgrad. med. J. (Suppl. May), 62–63 (1969).Google Scholar
  432. Menon, I.S., Cunliffe, W.J., Weightman, D., Dewar, H.A.: Phenformin and stanozolol in blood fibrinolytic activity. Brit. med. J. 1970I, 428.Google Scholar
  433. Merrill, J. P.: The Treatment of Renal Failure. New York: Grune & Stratton 1955.Google Scholar
  434. Mertens, H.G.: Anabole Steroide bei Muskelkrankheiten. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  435. Mezzena, R., Foresti, M., Trisotto, M., Bruni, G.: Studio di farmacologia umana sul quinbo-lone. G. Geront. 20, 361–378 (1972).Google Scholar
  436. Michaelsson, G., Petterson, L., Juhlin, L.: Purpura caused by food and drug additives. Arch. Derm. 109, 49–52 (1974).PubMedGoogle Scholar
  437. Milhorat, A.T.: Discussion on Dowben, R.M., Anabole Steroide bei Myopathien. Myopathien. Stuttgart: Georg Thieme Verlag 1965.Google Scholar
  438. Miranda, G., Jimenez, G., Lara, F.: Estudio comparativo en hepatitis viral tratada con anabolicos. Acta méd. costaric. 13, 155–159 (1970).Google Scholar
  439. Mitrofanov, V.S., Seliverstov, S.A., Markin, V.A.: Evaluation of the nerobol and prednisolone effectiveness in experimental myocardial infarction. Farmakol. i. Toksikol. 36, 316–319 (1973).Google Scholar
  440. Moench, A., Sarre, H., Sartorius, H.: Klinische und experimentelle Untersuchungen zur Frage der Beeinflussung von Nierenläsionen durch Sexualhormone, fetale Nieren-Trockenzellen und Heparin. Verh. dtsch. Ges. inn. Med. 60, 527–534 (1954).Google Scholar
  441. Moench, A., Sartorius, H.: Klinische Untersuchungen über Testosteronbehandlung beim ne-phrotischen Syndrom. Klin. Wschr. 32, 329–330 (1954).PubMedGoogle Scholar
  442. Moench, A., Vogt, A.: Studien zur Frage der Hormonbehandlung bei experimenteller Nephritis-Nephrose der weißen Ratte. Verh. dtsch. Ges. inn. Med. 64, 527–531 (1958).Google Scholar
  443. Moinade, S.: Action du trenbolone dans les dénutritions les cirrhoses et les ostéoporoses, étude a partir de 31 cas. Vie méd. 6, 605–608 (1974).Google Scholar
  444. Molino, N., Belluardo, C., Rosso, B.: Le sindromi disprotidemiche in geriatria e loro trattamento con un nuovo steroide anabolizzante derivato dall’androstano (2-formil-11 alfa-idrossi-delta-metiltestosterone). Nostra esperienza clinica. Clin. Ter. 66, 167–198 (1973).Google Scholar
  445. Molnar, G.D., Rosevaer, J.W., Gastineau, C.F., Moxness, K.E.: Effects of anabolic steroids on diabetic instability. Amer. J. med. Sci. 249, 280–290 (1965).PubMedGoogle Scholar
  446. Moore, F.D., Ball, R.M.: The Metabolic Response to Surgery. Springfield: Ch. C. Thomas 1952.Google Scholar
  447. Moore Ede, M.C., Burr, R.G.: Circadian rhythm of therapeutic effectiveness of oxymetholone in paraplegic patients. Clin. Pharmacol. Ther. 14, 448–454 (1973).PubMedGoogle Scholar
  448. Morin, J.-P.: Contribution a Fetude des anabolisants dans le traitement de la tuberculose pulmonale. Thesis, Marseille 1960.Google Scholar
  449. Morrison, B.O.: Use of analeptic, anti-depressant and anabolic drugs in treatment of the aged. J. Mich. St. med. Soc. 60, 723–726 (1961).Google Scholar
  450. Müting, D.: Die Wirkung einer Langzeitbehandlung mit einer anabolen Substanz (Nandrolon-decanoat) auf Proteinsynthese und-abbau sowie Ausscheidungs-und Entgiftungsfunktion der Leber bei chronischen Leberkrankheiten und Diabetes mellitus. Klin. Wschr. 42, 843–848 (1964).Google Scholar
  451. Muting, D.: Protein metabolism, excretion, and detoxication functions of the liver after long-term treatment of liver cirrhosis with an anabolic substance. Amer. J. dig. Dis. 10, 790–795 (1965).Google Scholar
  452. Murakami, M., Odake, K., Matsuda, T. et al.: Effects of anabolic steroids on anticoagulant requirements. Jap. Circ. J. 29, 243 (1965).PubMedGoogle Scholar
  453. Nanivadekar, S. A., Nanivadekar, A. S.: Gargoylism (Report of 3 cases and their treatment with nandrolone). J. J.J. Group Hosp. Grant med. Coll. 11, 176–181 (1966).Google Scholar
  454. Nasso, S., Pedretti, G., Levorato, F.: Tentativo di profilassi della varicella con steroidi anabol-izzanti ed antirachitic!. Minerva pediat. 16, 390–394 (1964).PubMedGoogle Scholar
  455. Navratil, J., Hrbek, J., Dvorak, M.: The therapeutic effect of stenolon spofa on female neurotic patients. Activ. nerv. sup. (Praha) 14, 102–103 (1972).Google Scholar
  456. Nethercott, J., Lester, R.S.: Azathioprine therapy in incomplete Behçet syndrome. Arch. Derm. 110, 432–434 (1974).PubMedGoogle Scholar
  457. Nikolaeva, L.F., Cherpachenko, N.M., Veselova, S.A., Sokolova, R.I.: Mechanisms of drug action on recovery processes of cardiac muscle in myocardial infarction. Circulation Res. 34/35, Suppl. III, 202–214 (1974).Google Scholar
  458. Nilsson, I. M., Hedner, U., Isacson, S.: Phenformin and ethyloestrenol in recurrent venous thrombosis. Acta med. scand., 198, 107–113 (1975).PubMedGoogle Scholar
  459. Nilsson, I.M., Isacson, S.: Thrombolytic therapy: long-term enhancement with oral agents. Effect of treatment with combined phenformin and ethyloestrenol on the coagulation and fibrinolytic systems. J. clin. Path. 25, 638–639 (1972).PubMedGoogle Scholar
  460. Novak, E.: The effect of fluoxymesterone on plasma lipids in men. Int. med. Digest 6, 17–23 (1971).Google Scholar
  461. Novak, E., Hendrix, J.W., Seckman, C.E., Penner, J.A.: A pharmacologic evaluation of fluoxy-mesterone in normal men. Curr. ther. Res. 16, 251–260 (1974).PubMedGoogle Scholar
  462. Nowy, H., Frings, H.D., Frost, H.: Effekte von Anabolika auf den Herzmuskel. Arzneimittel-Forsch. 13, 716–717 (1963b).Google Scholar
  463. Nowy, H., Frings, H.D., Seitz, W., Hashemi, I.: Effekte von Anabolika auf den Herzmuskel. Arzneimittel-Forsch. 13, 436–438 (1963a).Google Scholar
  464. Nyfos, L.: Durabolinbehandling af muskeldystrofi. Ugeskr. Laeg. 124, 1412 (1962).Google Scholar
  465. O’Grady, B.A.: The influence of drugs and diseases on the prothrombin time. Canad. J. med. Technol. 28, 140 (1966).Google Scholar
  466. Ojala, L.: Experiences on deca durabolin treatment of diabetic retinopathy. Acta ophthal. (Kbh.) 42, 519–522 (1964).Google Scholar
  467. O’Keefe, S.J.D., Sender, P.M., James, W.P.T.: Catabolic loss of body nitrogen in response to surgery. Lancet 1974II, 1035–1038.Google Scholar
  468. Oldershausen, H.-F.v.: Verfolgung der Radiojodbengalrosaelimination bei Ratten nach einma-liger sowie langfristiger Verabreichung verschiedener anaboler Steroide. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964a.Google Scholar
  469. Oldershausen, H.-F. v.: Verfolgung der Serumaktivitäten an Transaminasen und Aldolase bei Kaninchen und Hunden nach langfristiger Verabreichung von Methenolon. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964b.Google Scholar
  470. Oldershausen, H.-F. v.: Zur Abhängigkeit funktioneller Veränderungen der Leber von der chemischen Struktur, Dosis und Applikationsweise anaboler Steroide bei lebergesunden Patienten und Kranken mit Leberzirrhose. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964c.Google Scholar
  471. Oliveri, M.: La dimetazina quale terapia coadjuvante alla telecobalto-terapia in portatori di neoplasic polmonari. Gazz. med. ital. 126, 399 (1967).Google Scholar
  472. Olson, R. E.: Metabolic interventions in the treatment of infarcting myocardium. Circulation 40, Suppl. 4, IV-195–IV-201 (1969).Google Scholar
  473. Olsson, A.G., Orö, L., Rössner, S.: Effects of oxandrolone on plasma lipoproteins and the intravenous fat tolerance in man. Atherosclerosis 19, 337–346 (1974).PubMedGoogle Scholar
  474. Oosterhuis, J. A.: Retinopathia diabetica. Thesis, Amsterdam 1960. OosterhuisJ.A.: Discussion to a lecture of L.E.M. Valk. Ned. T. Geneesk. 107, II, 1775 (1963).Google Scholar
  475. Oosterhuis, J.A., Loewer-Sieger, D.H.: Behandeling van patienten met diabetische retinopa-thie met nandrolondecanoaat (Deca-durabolin). Ned. T. Geneesk. 106, II, 1574 (1962a).Google Scholar
  476. Oosterhuis, J.A., Loewer-Sieger, D.H.: Treatment of diabetic retinopathy with nandrolone-decanoate (decadurabolin). Ophthalmologica 144, 346–370 (1962b).PubMedGoogle Scholar
  477. Otter, G. den: The influence of anabolic substances on the nitrogen balance in surgical patients. Arch. chir. neerl. 12, 496–504 (1960).Google Scholar
  478. Overbeek, G.A.: Anabole Steroide, Chemie und Pharmakologie. Berlin-Heidelberg-New York: Springer-Verlag 1966.Google Scholar
  479. Oya, J.C. de, del Rio, A., Noya, M., Villanueva, A.: Decreased anticoagulant tolerance oxy-metholone in paroxysmal nocturnal haemoglobinuria. Lancet 1971II, 259.Google Scholar
  480. Page, C. W.: The treatment of debility: a controlled experience. Paper presented at a Symposium on Anabolic Therapy, Detroit, Michigan, March 1962.Google Scholar
  481. Panek, R.: Untersuchungen über den Mechanismus der strahlenschützenden Wirkungen der anabolen Steroide. Strahlentherapie 143, 211–218 (1972a).PubMedGoogle Scholar
  482. Panek, R.: Untersuchungen über den Mechanismus der strahlenschützenden Wirkung der anabolen Steroide. Strahlentherapie 143, 444–453 (1972b).PubMedGoogle Scholar
  483. Panek, R.: Untersuchungen über die Steigerung des strahlenschützenden Effekts der anabolen Steroide. Strahlentherapie 143, 559–569 (1972c).PubMedGoogle Scholar
  484. Pani, A.: L’associazione steroidi anabolizzanti ed insulinaglucosio nella terapia degli stati ipera-zotemici. Clin. ter. 46, 303–314 (1968).PubMedGoogle Scholar
  485. Panigada, G., Perletti, L., Magni, L., Giovannini, M.: Influenza di uno steroide anabolizzante sulla fenilalaninemia in lattanti distrofici. Minerva pediat. 20, 491–494 (1968).PubMedGoogle Scholar
  486. Paolino, J.S., Kaplan, D., Lazarus, R., Emmanuel, G., Diamond, H.S.: Phenformin and ethyl-oestrenol in scleroderma. Lancet 1972I, 1023.Google Scholar
  487. Parsons, F.M., McCracken, B.H.: The artificial kidney. Brit. med. J. 1959I, 740–751.Google Scholar
  488. Pasqualicchio, A., Pasoli, C.A., Forte, P.L., Corbellari, G.C.: Contributo al trattamento delle sindromi carenziali nel vecchio. Minerva med. 63, 2425–2430 (1972).Google Scholar
  489. Pateisky, K., Schinko, H., Haberler, H.: A study of the treatment of dystrophia musculorum progressiva with an anabolic steroid: nor-androstenolone decanoate. Acta endocr. (Kbh.) 63, 185–196 (1961).Google Scholar
  490. Patnaik, D.N., Nath, R., Pathak, I.C.: The effect of methandienone (an anabolic steroid) on nitrogen metabolism following surgical trauma. Indian J. med. Res. 57, 1751–1760 (1969).PubMedGoogle Scholar
  491. Payne, R.W.: Anabolism, appetite, and ambition. Kentucky Acad. gener. Pract. J. 5, 20–21 (1959).Google Scholar
  492. Pearson, S., Weissberg, J., McGavack, T.H.: Steroid studies. I. Metabolic effects of androstano-lone in aged people. J. Amer. Geriat. Soc. 2, 26 (1954).PubMedGoogle Scholar
  493. Pena, E. de la: Clinical use of oxymetholone in geriatrics. Sem. Méd. (Méx.) 27, 205–207 (1960).Google Scholar
  494. Pentycross, C.R., Toussis, D., McKinna, J.A., Lawler, S.D., Greening, W.P.: Effect of hormone therapy on mitogenic responses of lymphocytes from patients with cancer of the breast. Lancet 1973II, 177–179.Google Scholar
  495. Pergola, I.: Pren. méd. argent. 49, 274 (1962), cited by Tainter, M.L., Arnold, A., Beyler, A.L., Coulston, F., Potts, S.G.O., Roth, C.H.: A summary of the comparative therapeutic actions of stanozolol, an oral anabolic steroid. Clin. Med. 1964, 2089–2102.Google Scholar
  496. Pestalozzi, D.: Zur Behandlung der Retinopathia diabetica mit Deca-Durabolin. Ophthalmologica 147, 125–133 (1964).PubMedGoogle Scholar
  497. Petrochilos, A.M.: Steroides anabolisants sur la rétinopathie diabétique. Nosokom. Chron. 29, 201–203 (1967).Google Scholar
  498. Petzold, H., Matzkowski, H., Burckhardt, M.: Der Einfluß von Oral-Turinabol auf die „Thioacetamidzirrhose” der Rattenleber. Dtsch. Z. Verdau.- u. Stoffwechselkr. 29, 3 (1969).Google Scholar
  499. Pevchikh, V.V.: Anabolic steroids in the therapy of patients suffering from some diseases of the gastro-intestinal tract. Ter. Arkh. 41, 69–72 (1969).PubMedGoogle Scholar
  500. Pezold, F.A.: Anabole Hormone bei chronischer Hepatitis. Orale Therapie mit 1α, 7α-Bis(ace-tylthio)-17α-methyltestosteron. Munch. med. Wschr. 110, 2663–2668 (1968).PubMedGoogle Scholar
  501. Piatti, N., Pozzi, G.: Sperimentazione con 2-formil-17α-metilandrosta-l, 4-dien-11α, 17β-diol-3-one in clinica geriatrica. Clin. Ter. 74, 145–166 (1975).Google Scholar
  502. Picha, E.: Anabole Steroide bei der Strahlentherapie weiblicher Genitalkarzinome. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  503. Picha, E.: Neue Gesichtspunkte zur Anwendung anaboler Steroide in der gynäkologischen Strahlentherapie. Strahlentherapie 138, 300–322 (1969).PubMedGoogle Scholar
  504. Pohle, H.: Verlaufsbeobachtungen einzelner Leberfunktionsprüfungen unter oraler Applikation von Methenolon und 1-Phenylpropanol bei Lebergesunden. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  505. Polischuk, M.A.: The clinical assessment of the use of strophanthin and nerobol in cardiac insufficiency. Klin. Med. (Moskau) 48, 53–56 (1970).Google Scholar
  506. Porsio, A.: Controlled clinical trials of a new anabolic agent in chronic TB patients. Clin. ter. 37, 502–518 (1966).PubMedGoogle Scholar
  507. Porsio, A.: Ricerche cliniche controllate su due anabolizzanti ad azione protratta. Minerva med. 59, 824–828 (1968).PubMedGoogle Scholar
  508. Porter, R., Knight, J. (ed.): Energy metabolism in trauma. A Ciba Foundation Symposium. London: J. & A. Churchill 1970. Porto, A. L.: O tratamento testosterónico da cirrose hepática. Thésis, Coimbra 1968.Google Scholar
  509. Poser, G., Kluthe, R., Adler, P.: Zur Therapie des nephrotischen Syndroms. Med. Klin. 61, 432–435 (1966).Google Scholar
  510. Pozzetto, M.H.: Un anabolisant, le phenylpropionate de nandrolone, en pneumophtisiologie. Rev. Lyon Med. 10, 961–968 (1961).Google Scholar
  511. Prikhozan, V.M.: Pathogenesis of the nervous system affection in diabetes mellitus. Probl. Endokrinol. Gormonterap. 14, 14–18 (1968).Google Scholar
  512. Probst, J.-H.: Treatment of children suffering from disorders of muscular movement with dura-bolin and decadurabolin. Proc. VII. Intern. Congr. Neurology 2, 645–652 (1961).Google Scholar
  513. Pruss, G.M., Markovskaia, G.I., Bosko, A.P.: In: Profilaktika i lechenie koronarnoi i serdechnoi nedostatochnosti. Leningrad 1967.Google Scholar
  514. Quack, G.: Primobolan als Zusatztherapie bei der Strahlenbehandlung. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  515. Quack, G., Gaebel, E.: Primobolan-Depot in der Strahlentherapie. Med. Mitt. Schering 23, 16 (1962)Google Scholar
  516. Rabier, M.: Utilisation d’un anabolisant dans la tuberculose pulmonaire du noir africain. Afr. méd. 95 (1971).Google Scholar
  517. Rabinowitz, J.L., Chase, G.D., Myerson, R.M.: Failure of anabolic steroid, oxymetholone, to influence survival time of dystrophic mice. Amer. J. med. Sci. 246, 456–458 (1963).PubMedGoogle Scholar
  518. Ravens, K.G.: Der Einfluß von anabolen Hormonen und von Diät auf den myokardialen Gehalt an energiereichen Phosphaten während der Infarktheilung. Verh. dtsch. Ges. Kreisl.-Forsch. 36, 314–319, 389 (1970).Google Scholar
  519. Rebora Togno, F.: El decanoato de nandrolona como coadyuvante del medico o quirurgico de la tuberculosis pulmonar. Sem. Méd. (Méx.) 67, 146–150 (1971).Google Scholar
  520. Rehn, J., Spinner, M.-E.: Die Anwendung anabol wirksamer Hormone in der Chirurgie. Med. Welt (Stuttg.) 25, 1401–1405 (1962).Google Scholar
  521. Reiss, M., Hillman, J.C., Reiss, J., Daley, N., Haylock, S.: Influence of anabolic hormones on phenylalanine metabolism. I. Studies on chronic phenylketonuric patients. J. ment. Defic. Res. 10, 20 (1966b).Google Scholar
  522. Reiss, M., Sideman, M.B., Plichta, E.S.: Influence of anabolic hormones on phenylalanine metabolism. II. Studies in animals. J. ment. Defic. Res. 10, 130–140 (1966a).PubMedGoogle Scholar
  523. Ren, G. de, Meyer, D., Simon, G.: Utilisation du phenyl-propionate de nor-androstenolone en phtisiologie. Vie méd. 42, 739–751 (1961).Google Scholar
  524. Resan, T.K., Shahidi, N.T., Korst, D.R.: Effect of phenobarbital on testosterone-induced ery-thropoiesis. J. Lab. clin. Med. 79, 187 (1972).PubMedGoogle Scholar
  525. Rigberg, S.V., BrodskyJ.: Potential roles of androgens and the anabolic steroids in the treatment of cancer. A review. J. Med. 6, 271–290 (1975).Google Scholar
  526. Riordan, D. J., Browne, P.A.: The treatment of secondary deposits in bone from carcinoma of the breast with radio-active phosphorus and durabolin. J. Irish med. Ass. 99, 40–44 (1961).Google Scholar
  527. Roberts, H.J.: Radiotherapy in herpes zoster. Lancet 1965II, 1074.Google Scholar
  528. Roberts, H.J.: Timed repetitive ankle jerk (TRAJ) responses in ‘early’ diabetic neuropathy: Diagnostic and therapeutic observations, with particular reference to the effects of nandro-lone. Diabetes 18, 370–371 (1969).Google Scholar
  529. Roberts, P.S., Burkat, R.K.: Effects of biguanides on reactions of thrombin and on 1-stage prothrombin time of standard human plasma. Ann. N.Y. Acad. Sci. 714 (1968).Google Scholar
  530. Robinson, B.H.B., Hawkins, J.B., Ellis, J.E.: Decreased anticoagulant tolerance with oxymetholone. Lancet 1971I, 1356.Google Scholar
  531. Robinson, R.W., LeBeau, R.J.: Effect of oxandrolone on hyperlipemia. Circulation 42, Suppl. 3, 55 (1970).Google Scholar
  532. Robson, A.M., Ashcroft, R., Clarkson, B.A., Horn, D.B., Kerr, D.N.S.: The effect of an anabolic steroid (Deca-Durabolin) on urea production. Proc. europ. Dialys. Transpl. Ass. (EDTAProc.) 1, 159 (1964a).Google Scholar
  533. Robson, A.M., Ashcroft, R., Clarkson, B.A., Horn, D.B., Kerr, D.N.S.: Diet and anabolic steroids. In: Sheldon, S., Cook, S. (Eds.): Acute Renal Failure. Oxford: Blackwell 1964b.Google Scholar
  534. Robson, A.M., Ashcroft, R., Clarkson, B.A., Horn, D.B., Kerr, D.N.S.: Urea metabolism in chronic uremia: Effect of protein restriction, anabolic steroids and antibiotics. In: Berlyne, G.M. (Ed.): Nutrition in Renal Disease. Edinburgh: Livingstone 1968.Google Scholar
  535. Rohwedder, H.J.: Beobachtungen bei der Anwendung anaboler Steroide bei Kindern mit ne-phrotischem Syndrom. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  536. Rosnick, M.J.: Use of anabolic steroid, stanozolol, to promote weight gain in underweight patients. Clin. Med. 71, 989 (1964).PubMedGoogle Scholar
  537. Rouher, F., Serpin, G.: Action du phenyl-propionate de nor-androstenolone dans la retinopa-thie diabétique. Presse méd. 72, 2211–2212 (1964).PubMedGoogle Scholar
  538. Roy, J. A.: Study of the correction of protein disorders seen in the course of alcoholic cirrhosis by androstanolone. Thesis, Bordeaux 1961.Google Scholar
  539. Rozman, C., Urbano, A., Galera, H.: Lebertoxizität der anabolen Steroide. Münch. med. Wschr. 113, 965–967 (1971).PubMedGoogle Scholar
  540. Ruprecht, K. W.: Diabetische Retinopathie. Med. Welt 26, 1822–1825 (1975).PubMedGoogle Scholar
  541. Sachs, B.A., Wolfman, L.: Effect of oxandrolone on plasma lipids and lipoproteins of patients with disorders of lipid metabolism. Metabolism 17, 400–410 (1968).PubMedGoogle Scholar
  542. Saito, T., Saito, M.: Studies on the action mechanism of anabolic steroids. II. The effect on the serum glycoproteins. Iryo 20, 1154–1161 (1966).PubMedGoogle Scholar
  543. Saito, T., Shirata, S., Nakamura, R., Saito, M.: Studies on the action mechanisms of anabolic steroids. I. Clinico-pharmacological studies on their effects upon the far advanced pulmonary tuberculous patients. Iryo 20, 565–572 (1966).PubMedGoogle Scholar
  544. Sansoy, P. M., Naylor Roy, A., Shields, L. M.: Anabolic action and side effect of oxandrolone in 34 mental patients. Geriatrics 26, 139–143 (1971).PubMedGoogle Scholar
  545. Santalo, M., Echevarne, F.: Untersuchungen des Mongolismus und seine Behandlung mit Norandrostenolonphenylpropionat. Med. Welt 34, 1683–1686 (1963).PubMedGoogle Scholar
  546. Sarre, H.: Die Therapie des akuten Nierenversagens. Mkurse ärztl. Fortbild. 13, 298 (1963).Google Scholar
  547. Sarre, H.: Einführung zu „Anabolika bei Nierenerkrankungen”. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  548. Sarre, H.: Diuresetherapie. Med. Klin. 61, 2009–2013 (1966).PubMedGoogle Scholar
  549. Saskin, E., Waldman, S., Pelner, L.: Diabetic retinopathy; a new approach to therapy with a steroid hormone testosterone propionate. Amer. J. Ophthal. 3, 613 (1951).Google Scholar
  550. Schilling, A., Finkel, H.E.: Ancillary measures in treatment of myeloma. Use of immune serum globulin, fluoride, or androgen. Arch. intern. Med. 135, 193–196 (1975).PubMedGoogle Scholar
  551. Schimmelpfennig, W.: Anabole Steroide und Nierenerkrankungen. Dtsch. Gesundh.-Wes. 21, 97–100 (1965).Google Scholar
  552. Schindler, H.: Marfan-Syndrom mit Morbus Addison und Akromegalie. Wien. med. Wschr. 125, 643–644 (1975).PubMedGoogle Scholar
  553. Schindler, H., Korn, A.: Anabole Steroide und ihre hormonellen Nebenwirkungen. Munch. med. Wschr. 107, 479 (1965).PubMedGoogle Scholar
  554. Schnack, H.: Tierexperimentelle Untersuchungen mit anabolen Steroiden. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964a.Google Scholar
  555. Schnack, H.: Klinische Untersuchungen mit Steroiden der Primobolan-Reihe im Kurzversuch. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964b.Google Scholar
  556. Schnack, H.: Klinische Erfahrungen über Langzeitbehandlung von Leberzirrhosen mit anabolen Steroiden der Primobolan-Reihe. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964c.Google Scholar
  557. Schnack, H., Schobel, B., Wewalka, F.: Therapie der Leberzirrhose mit anabolen Steroiden. Wien. klin. Wschr. 74, 833–836 (1962).Google Scholar
  558. Schoppe, W.-D.: Die Beeinflussung des Eiweißstoffwechsels lungenoperierter Patienten durch anabole Steroide bei postoperativer Zufuhr von kliniksüblicher Kost. Dissertation, Düssel-dorf 1971.Google Scholar
  559. Schrogie, J.J., Solomon, H.M.: Hazards of multiple drug therapy in patients taking coumarin anticoagulants. Circulation 34, Suppl. III-210–III-211 (1966).Google Scholar
  560. Schrogie, J.J., Solomon, H.M.: The anticoagulant response to bishydroxycoumarin. II. The effect of D-thyroxine, clofibrate, and norethandrolone. Clin. Pharmacol. Ther. 8, 70–77 (1967).PubMedGoogle Scholar
  561. Schumacher, H.: Klinik und Pathophysiologic der diabetischen Retinopathie. Med. Welt (Berl.) 18, 96–100 (1967).Google Scholar
  562. Schwarz, F.K.T.: Revitalisierung beim alternden Menschen durch eine multivalente Vitamin-Mineral-Anabolikum-Kombination. Hippokrates 38, 900–902 (1967).PubMedGoogle Scholar
  563. Schwarz, W., Kutzsche, A.: Elektronenmikroskopische Untersuchungen über die anabole und katabole Wirkung von Dexamethason und Methenolonester auf Fibroblasten in vitro. Klin. Wschr. 44, 979–982 (1966).PubMedGoogle Scholar
  564. Scuderi, G., Sborgia, G.: Terapia della retinopatia diabetica. Clin. Ter. 70, Suppl. 3, 42–61 (1974).Google Scholar
  565. Segers, J., Nuyts, J.A.: Clinical trial with oxymetholone in a group of schizophrenic patients. Acta neurol. belg. 64, 736–745 (1964).PubMedGoogle Scholar
  566. Seifert, E.: Methenolonazetat und-önanthat bei chronischer Hepatitis und Leberzirrhose. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  567. Selye, H.: On the protective action of testosterone against the kidney damaging effect of sublimate. J. Pharmacol. exp. Ther. 68, 454–457 (1940).Google Scholar
  568. Selye, H.: Catatoxic steroids. Canad. med. Ass. J. 101, 51–52 (1969).PubMedGoogle Scholar
  569. Selye, H.: Prevention of colchicine intoxication by catatoxic steroids. Endocrinologia Exp. 4, 71–76 (1970a).Google Scholar
  570. Selye, H.: Resistance to picrotoxin poisoning induced by catatoxic steroids. Agents and Actions 1, 133–135 (1970b).PubMedGoogle Scholar
  571. Selye, H.: Resistance to various pesticides induced by catatoxic steroids. J. Amer. med. Ass. 214, 2072 (1970c).Google Scholar
  572. Selye, H.: Hormone und Widerstandsfähigkeit. Münch. med. Wschr. 112, 1401–1407 (1970d).PubMedGoogle Scholar
  573. Selye, H.: Protection by catatoxic steroids against cycloheximide intoxication. Toxical appl. Pharmacol. 17, 721–725 (1970e).Google Scholar
  574. Selye, H.: Conditioning of catatoxic steroid actions by the thyroid. J. Med. 1, 43–55 (1970f).PubMedGoogle Scholar
  575. Selye, H.: Protection against LSD by various steroids. Life Sci. 10, 1135–1140 (1971).Google Scholar
  576. Selye, H.: Hormones and resistance. Berlin-Heidelberg-New York: Springer-Verlag 1971.Google Scholar
  577. Selye, H., Jelinek, J., Krajny, M.: Prevention of digitoxin poisoning by various steroids. J. Pharm. Sci. 58, 1055–1059 (1969).PubMedGoogle Scholar
  578. Selye, H., Solymoss, B.: Protection by catatoxic steroids against meprobamate. Neuropharmacology 9, 327–332 (1970).PubMedGoogle Scholar
  579. Selye, H., Yeghiayan, E., Mandeville, R.: Protection by catatoxic steroids against dihydro-tachysterol intoxication. Atherosclerosis 11, 321–331 (1970).PubMedGoogle Scholar
  580. Selye, H., Yeghiayan, E., Mecs, I.: Prevention of nicotine intoxication by catatoxic steroids. Arch. int. Pharmacodyn. 183, 235–238 (1970).PubMedGoogle Scholar
  581. Seneca, H.: Endotoxic shock and hyperpyrexia in urological practice. J. Amer. Geriat. Soc. 16, 733–744 (1968).PubMedGoogle Scholar
  582. Seneca, H., Peer, P.: Effect of estrogens and anabolic steroids on renal infections in normal and immunized/sensitized rats and mice. Bact. Proc. 99 (1967a).Google Scholar
  583. Seneca, H., Peer, P.: Effect of estrogens and anabolic steroids on experimental infections. International Congress of Chemotherapy, Vienna 1967b.Google Scholar
  584. Sereni, F., Piceni-Sereni, L., De Ritis, L.: Influence of an anabolising steroid on the metabolic balance of nitrogen in the nephrotic syndrome. Minerva pediat. 11, 1124–1128 (1959).PubMedGoogle Scholar
  585. Settel, E.: Protein metabolism in the elderly: A cross-over study of a hormonal anabolic agent (methandrostenolone) and a non-hormonal agent (enzyme-vitamin complex). J. Amer. Geriat. Soc. 12, 538–547 (1964).PubMedGoogle Scholar
  586. Sevin, R., Cuendet, J.F.: La rétinopathie diabétique. Son traitement médical. Praxis 60, 612–614(1971).Google Scholar
  587. Shahidi, N.T.: Barbiturate effect in androgen therapy. New Engl. J. Med. 287, 309 (1972).PubMedGoogle Scholar
  588. Sharma, K.K., Misra, M.B., Dixit, B.B., Sastri, P.S.R.: Effect of ethyloestrenol on serum cholesterol in rabbits. Indian Drugs Annual 17–19 (July 1975).Google Scholar
  589. Shils, M.E.: Renal disease and metabolic effects of tetracycline. Ann. intern. Med. 58, 389 (1963).PubMedGoogle Scholar
  590. Siegmund, G.: Die Anwendung eines anabolen Steroids bei Erkrankungen des rheumatischen Formenkreises. Med. Klin. 58, 995–998 (1963).Google Scholar
  591. Sigler, H., Issekutz, B.: Effects of anabolic steroids in chronic renal failure. Arch. intern. Med. 120, 408–416 (1967).PubMedGoogle Scholar
  592. Silk, R.E.: Management of protein and fat losses in surgical patients. J. Albert Einstein med. Center 10, 181–187 (1962).Google Scholar
  593. Sim, A.W., Henderson, P.S., Vies, J., van der: The effect of steroids on the biosynthesis of collagen in rat skin. Paper presented at III. European Symposium on Connective Tissue Research, Turku, August 1972.Google Scholar
  594. Sim, A.W., Picton, W., Fox, P.K., Walker, G.B.: The effect of topical corticosteroids on the metabolism of dermal collagen. In: Proceedings of Glaxo Symposium on Mechanism of Action of Corticosteroids, Edinburgh-London: Livingstone 1975.Google Scholar
  595. Sinitzin, P.D., Agafonowa, G.A.: Clinical evaluation of the effect of anabolic preparations on the effectiveness of treatment in peptic ulcer. Sovetsk. Med. 150–151 (1975).Google Scholar
  596. Skikantia, S.G., JayaRao, K.S., Prasad, P.S.: Effect of a C-17 alkylated steroid, methylandro-stenolone, on plasma lipids of normal subjects. Amer. J. med. Sci. 254, 201 (1967).Google Scholar
  597. Smith, C., Johnson, P.C.: Anabolic effect of 19-nortestosterone phenylpropionate in underweight geriatric women. J. Amer. Geriat. Soc. 9, 304–311 (1961).Google Scholar
  598. Snow, E.W.: Stanozolol, a new anabolic agent: Clinical observations in seventy-two patients. Med. Tms 91, 149–157 (1963).Google Scholar
  599. Snyder, D., Brest, A. B.: Chronic renal insufficiency treated with anabolic steroid. Effect on acid-base balance, protein metabolism and hematopoiesis. J. Amer. Geriat. Soc. 14, 21 (1966).PubMedGoogle Scholar
  600. Soecknick, H.: Fertabolin in der Geriatric Prakt. Arzt 299, 509–526 (1972).Google Scholar
  601. Sokolova, T.S., Fedotova, A.M., Balashova, U.A.: The complex employment of anabolic hormones and antihistamine preparations in treating allergic diseases in early childhood. Pediatriia (Moskwa) 44, 34–39 (1965).Google Scholar
  602. Soler-Argilaga, C.: Esteroides anabolizantes. II. algunos aspectos de nuestra experiencia clinica sobre esteroides anabolizantes. An. Med. (Med.) 50, 203–219 (1964).Google Scholar
  603. Sons, W. A.: Stanozolol in urological surgery. Dia Medico 43, 1669–1670 (1971).Google Scholar
  604. Solymoss, B., Toth, S., Varga, S., Selye, H.: Protection by spironolactone and oxandrolone against chronic digitoxin or indomethacin intoxication. Toxical appl. Pharmacol. 18, 586–592 (1971).Google Scholar
  605. Spencer, D.A.: Letter to the editor. Med. News, No. 228, 12 (1967).Google Scholar
  606. Stenzel, K.H., Cheigh, J.S., Sullivan, J.F., Tapia, L., Ruggio, R.R., Rubin, A.L.: Clinical effects of bilateral nephrectomy. Amer. J. Med. 58, 1, 69–75 (1975).PubMedGoogle Scholar
  607. Stepan, J., Bremova, A.: Stromba bei Erkrankungen des Bewegungsapparates. Med. Klin. 62, 1470–1474 (1967).PubMedGoogle Scholar
  608. Stöckl, W., Geyrhofer, K.: Die Beeinflussung der Antikörperbildung durch Sanabolicum. Wien. tierärztl. Mschr. 52, 94–98 (1965).Google Scholar
  609. Stone, M.C.: Idiopathic hyperglyceridemia treated with methyltestosterone and methandienone. Lancet 1963I, 477.Google Scholar
  610. Stone, M.C.: Elevation of serum-cholesterol by an anabolic steroid. Lancet 1964I, 474.Google Scholar
  611. Stuhlfauth, K., Frost, H.: Medikamentöse Rehabilitation und Behandlung der Hypotonie mit Steroidhormonen. Munch. med. Wschr. 106, 498–502 (1964).PubMedGoogle Scholar
  612. Stur, O.: Durabolinbehandlung bei infantiler spinaler Muskelatrophie. Wien. klin. Wschr. 72, 54–55 (1960).Google Scholar
  613. Svendsen, B.B.: Negative results of treatment with nortestosterone in urinary incontinency in women with senile dementia. Nord. Med. 62, 1516–1517 (1959).Google Scholar
  614. Szold, E.: Die Wirkung von Methylandrostendiol und Norandrostenolon in experimenteller Uramie. (Hungarian). Magy. Sebész. 12, 368–369 (1959).Google Scholar
  615. Szold, E., Szendroi, Z., Weisz, P., Pinter, I., Desi, I., Kadas, T.: Anabolic steroids in uremia. Lancet 1959II, 368–369.Google Scholar
  616. Tache, Y., Tache, J., Selye, H.: Inhibition of the effects of Alfathesin and other steroid anesthetics by catatoxic steroids in rats. Arzneimittel-Forsch. 25, 1603–1606 (1975).Google Scholar
  617. Tainter, M.L.: Anabolic steroids in the management of the diabetic patient. N.Y. St. J. Med. 64, 1001–1009 (1962).Google Scholar
  618. Tamburro, C., Leevy, C.M.: Protein clotting factor synthesis in liver disease. Gastroenterology 52, 325 (1967).Google Scholar
  619. Tan, R.S.H., Copeman, P. W.M.: Blood hypercoagulability causing leg ulcerations. Brit. J. Derm. 91, 46–48 (1974).Google Scholar
  620. Tec, L.: Durabolin in anorexia nervosa. Amer. J. Psychiat. 120, 282 (1963).PubMedGoogle Scholar
  621. Tec, L.: Anorexia nervosa—follow-up on a special method of treatment. Amer. J. Psychiat. 127, 1702 (1971).PubMedGoogle Scholar
  622. Tec, L.: Nandrolone in anorexia nervosa. J. Amer. med. Ass. 229, 1423 (1974).Google Scholar
  623. Thaysen, J.H.: Protein metabolism. Internat. Symposion, Leyden. Berlin-Göttingen-Heidelberg: Springer 1962.Google Scholar
  624. Tichy, A., Dolecek, R., Klabusay, L.: Experimental cardiopathy in burned rats. Rozhl. Chir. 42, 230–236 (1963).PubMedGoogle Scholar
  625. Tirkina, T.N., Aleksandriva, L.M., Klyachko, V.R., Mazovetsky, A.G.: Pyridinolcarbamate (anginin) in the treatment of diabetic angiopathy. Ter. Arkh. 46, 107–110 (1974).PubMedGoogle Scholar
  626. Tolentino, P.: Protein anabolic steroid hormones and antibody formation. Ann. paediat. 199, 467–471 (1962).PubMedGoogle Scholar
  627. Tolentino, P.: Gli steroidi anabolizzanti nella terapia delle epatiti virali. Epatologia 12, 461–469 (1966).Google Scholar
  628. Tolentino, P.: Anabolische Steroide und Immunität. Münch. med. Wschr. 113, 953–955 (1971).PubMedGoogle Scholar
  629. Tolentino, P., Terragna, A., Jannuzzi, C.: Ormoni steroidei ed anticorpopoiesi. Mancata azione di stimolo da parte di steroidi proteino-anabolici nella somministrazione distanziata dall’antigene o nella risposta anamnestica. Ann. Sclavo 6, 439–444 (1964).Google Scholar
  630. Toni, E. de: Gli effetti degli steroidi anabolizzanti sul ricambio creatinico nella miodistrofia progressiva. Clin. pediat. 41, 441–445 (1959).Google Scholar
  631. Toni, E. de: Treatment of progressive muscular dystrophy in particular with the anabolic steroids. Acta endocr. (Kbh.) 63, 175–184 (1961).Google Scholar
  632. Toni, G. de: Sulla possibilitá di limitare o addirittura inibire la creatinuria patologica della miodistrofia progressiva mediante l’uso di forti dosi di steroide anabolizzanti. Boll Soc. ital. Biol. sper. 35, 110–114 (1959).Google Scholar
  633. Trocme, P., Roy, J.: Essai de correction par l’androstanolone des troubles du métabolisme des protides chez les cirrhotiques. Sem. Hôp. Paris 38, 22–25 (1962).Google Scholar
  634. Trusov, V.V., Vakhrushev, Y.M.: Evaluation of the therapeutic effect of the anabolic steroid agent androstanasol in patients with chronic gastritis. Vrach. Delo 8, 39–42 (1973).PubMedGoogle Scholar
  635. Trusov, V.V., Vakhrushev, Y.M., Oreshkov, T.M.: Clinical evaluation of the therapeutic action of a new soviet-made preparation—androstanasol in patients with peptic ulcer. Ter. Arkh. 46, 96–100 (1974).PubMedGoogle Scholar
  636. Turner, R.L.: Combined androgenic and cytotoxic therapy in carcinoma of the breast. Paper read at a Symposium at the University Dept. of Surgery, Royal Infirmary, Sheffield, Nov. 1966.Google Scholar
  637. Tweedle, D.E.F., Walton, C., Johnston, I.D.A.: The effect of a long-acting anabolic steroid on nitrogen balance during the anabolic phase of recovery from abdominal surgery. Brit. J. Surg. 59, 300 (1972).PubMedGoogle Scholar
  638. Tweedle, D.E.F., Walton, C., Johnston, I.D.A.: The effect of an anabolic steroid on postoperative nitrogen balance. Brit. J. clin. Pract. 27, 130–132 (1973).PubMedGoogle Scholar
  639. Udupa, K.B., Reissmann, K.R.: Stimulation of granulopoiesis by androgens without concomitant increase in colony-stimulating factor. Clin. Res. 22, 609 A (1974).Google Scholar
  640. Vadasz, I.: Effect of nandrolone decanoate on some forms of pulmonary tuberculosis. Arzneimit-tel-Forsch. 19, 100–103 (1969).Google Scholar
  641. Vaisrub, S.: Intravascular factors in diabetic retinopathy. Editorial, J. amer. med. Ass. 233, 1303 (1975).Google Scholar
  642. Vakhrushev, Y.M.: The experience of the therapeutic use of anabolic steroid of nerobol in combination with quateron in exacerbation of peptic ulcer. Terap. Arkh. 43, 26–30 (1971).Google Scholar
  643. Vakhrushev, Y.M., Trusov, V.V.: Comparative characteristics of therapeutic efficacy of a number of medicinal combinations of patients with peptic ulcer. Terapevt. Arkh. 47, 108–113 (1975).Google Scholar
  644. Valk, L. E.M.: Influence favorable du phénylpropionate de 19-nor-androsténolone sur rétinopa-thie diabétique. Bull. Soc. franc. Ophtal. 72, 596–608 (1959).PubMedGoogle Scholar
  645. Valk, L.E.M.: Successen en tegenslagen bij de behandeling van diabetische retinopathie met anabole steroiden gedurende de laatste vijf jaren. Ned. T. Geneesk. 107, II, 1773–1776 (1963).Google Scholar
  646. Valk, L.E.M.: Nandrolone decanoate, a useful anabolic steroid in diabetic retinopathy instead of destruction of the hypophysis. Excerpta med. Intern. Congr. Ser. 74, 36 (1964).Google Scholar
  647. Valk, L.E.M., Vergroesen, J.A.J.: Een gunstige invloed van nandrolon decanoaat op oog en nier in enige gevallen van de ziekte van Kimmelstiel-Wilson; enige moeilijkheid bij de beoordeling van het nierbiopt. Ned. T. Geneesk. 113, 99 (1969).Google Scholar
  648. Vasiukova, E.A., Margolis, M.G.: Complex treatment of patients with diabetes mellitus with diabetic retinopathy. Klin. Med. (Moskau) 53, 78–82 (1975).Google Scholar
  649. Vasiukova, E.A., Zefirova, F.S., Briskin, A.L: Anabolic steroids in the treatment of endocrine disease. Ter. Arkh. 41, 9–15 (1969).PubMedGoogle Scholar
  650. Vassella, F., Rossi, E., Aebi, U., Richterich, R.: Anabole Steroide bei progressiver Muskeldy-strophie. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  651. Vere, D.W., Fearnley, G.R.: Suspected interaction between phenindione and ethyloestrenol. Lancet 1968II, 281. Google Scholar
  652. Verevkin, A.M., Pevchikh, V.V.: Changes in gastric and hepatic function in peptic ulcer during treatment with an anabolic steroid preparation—nerobol. Ter. Arkh. 44, 36–39 (1972).PubMedGoogle Scholar
  653. Vermeulen, A.: Influence of anabolic steroids on secretion and metabolism of Cortisol. In: Structure and metabolism of corticosteroids. London-New York: Academic Press 1964.Google Scholar
  654. Vermeulen, A., Demeulenaere, L.: Einfluß anaboler Steroide auf Leberenzyme. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  655. Vermeulen, H. J.: 17β-hydroxy-4-estren-3-one laurate, a new long-acting anabolic steroid. Arz-neimittel-Forsch. 18, 1458–1460 (1968).Google Scholar
  656. Verstraete, M.: The position of long-term stimulation of the endogenous fibrinolytic system: Present achievements and clinical perspectives. Thrombos. Diathes. haemorrh. 34, 613–622 (1975).Google Scholar
  657. Verwilghen, R., Louwagie, A., Waes, J., Vandenbroucke, J.: Anabolic agents and relative po-lycythaemia. Brit. J. Haemat. 12, 712–716 (1966).PubMedGoogle Scholar
  658. Viallier, J.: Action de l’androstanolone base chez les tuberculeux pulmonaires. Lyon méd. 90, 32 (1958).PubMedGoogle Scholar
  659. Vilanova, J.: The use of methandrostenolone (Dianabol) in improving nutrition in geriatric patients. J. med. Soc. N. Jersey 59, 65–68 (1962).Google Scholar
  660. Vlavianos, G., Seaman, G., Vlavianos, M.: A further clinical study of anabolic steroids in incontinence. Amer. J. Psychiat. 118, 539–542 (1961).PubMedGoogle Scholar
  661. Voss, H.E.: Androgene und Nieren. In: Voss, H.E., Oertel, G.: Androgene I, pp.551–556. Berlin-Heidelberg-New York: Springer-Verlag 1973 a.Google Scholar
  662. Voss, H.E.: Androgene und Muskulatur. In: Voss, H.E., Oertel, G.: Androgene I, pp.559–566. Berlin-Heidelberg-New York: Springer-Verlag 1973b.Google Scholar
  663. Voss, H.E.: Wirkung der Androgene auf die Wundheilung: In: Voss, H.E., Oertel, G.: Androgene I, pp.576–577. Berlin-Heidelberg-New York: Springer-Verlag 1973c.Google Scholar
  664. Voss, H.E.: Die anti-hypercholesterinämische Wirkung der Androgene. In: Voss, H.E., Oer-tel, G.: Androgene I, pp.604–606. Berlin-Heidelberg-New York: Springer-Verlag 1973d.Google Scholar
  665. Walker, I.D., Davidson, J.F., Young, P., Conkie, J.A.: Plasma fibrinolytic activity following oral anabolic steroid therapy. Thrombos. Diathes. haemorrh. 34, 236–245 (1975 a).Google Scholar
  666. Walker, I.D., Davidson, J.F., Young, P., Conkie, J.A.: Effect of anabolic steroids on plasma antithrombin III, α 2-macroglobulin and α 1-antitrypsin levels. Thrombos. Diathes. haemorrh. 34, 106–114 (1975b).Google Scholar
  667. Walsh, F.M., Harris, L.D., Schipke, J.M.: The treatment of diabetic vitreous hemorrhages. Minerva Med. 46, 641–644 (1963).Google Scholar
  668. Wardle, E.N.: Study of the lipid-lowering action of choloxin and nilevar in patients with chronic renal failure. Postgrad. med. J. 50, 737–740 (1974).PubMedGoogle Scholar
  669. Watkin, D.M., Parsons, J.M., Yiengst, M.J., Shock, N.W.: Metabolism in the aged: the effect of stanolone on the retention of nitrogen, potassium, phosphorus, and calcium and on the urinary excretion of 17-keto, 11-oxy, and 17-hydroxy steroids in eight elderly men on high and low protein diets. J. Gerontol. 10, 268–287 (1955).PubMedGoogle Scholar
  670. Watschinger, B.: Verlaufsbeobachtungen bei Nephrosekranken. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  671. Watts, G.T., Baddeley, M.R., Wellings, R., Evans, J.: The nature of wound healing: Experimental tensile strength studies with deca durabolin and S35. Ann. Surg. 162, 109–112 (1965).PubMedGoogle Scholar
  672. Watzman, N., Kinnard, W.J., Aceto, M.D., Buckley, J.P.: Effects of certain compounds on experimental muscular dystrophy. J. pharm. Sci. 51, 1090–1095 (1962).PubMedGoogle Scholar
  673. Weber, H., Hagge, W.: Über die erfolgreiche Behandlung der Zystinose mit einem Anabolicum. Arch. Kinderheilk. 168, 2 (1963).Google Scholar
  674. Weiner, M., Siddiqui, A.A., Bostanci, N., Dayton, P.G.: Drug interactions: The effect of combined administration on the half-life of coumarin and pyrazolone drugs in man. Fed. Proc. 24, 153 (1965).Google Scholar
  675. Weiner, M., Siddiqui, A.A., Shahani, R.T., Dayton, P.G.: Effect of steroids on disposition of oxyphenbutazone in man. Proc. Soc. exp. Biol. Med. 124, 1170–1173 (1967).PubMedGoogle Scholar
  676. Weissel, W.: Anaboles Hormon bei malignem oder kompliziertem Diabetes mellitus. Wien. klin. Wschr. 74, 234–236 (1962).PubMedGoogle Scholar
  677. Weller, O.: Die Wirkung von Methenolon auf die gesunde Leber. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964a.Google Scholar
  678. Weller, O.: Die Verwendung von Methenolon bei akuten und chronischen Leberparenchym-Erkrankungen. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964b.Google Scholar
  679. Weller, O., Voegt, H.: Therapie der Leberzirrhose. Therapiewoche 12, 665–668 (1962).Google Scholar
  680. Wells, R.: Prednisolone and testosterone propionate in cirrhosis of the liver. A controlled trial. Lancet 1960II, 1416–1419.Google Scholar
  681. Wenzel, B., Bünte, H.: Die Verwertung parenteral zugeführter Aminosäuren nach chirurgischen Operationen. Med. Ernähr. 9 (1968).Google Scholar
  682. Werner, S.C.: Clinical syndromes associated with gonadal failure in men. Amer. J. Med. 3, 52–66 (1947).PubMedGoogle Scholar
  683. Wernze, H.: Aufnahme und Ausscheidung von Bromsulfophthalein unter dem Einfluß anaboler Hormone durch die Leberzelle der Ratte. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964a.Google Scholar
  684. Wernze, H.: Die Leberfunktion unter dem Einfluß verschiedener Testosteronabkömmlinge (Un-tersuchungen von Serum-Fermenten und Bromsulfophthalein-Ausscheidung). In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964b.Google Scholar
  685. West, H.F., Lewis-Faning, E.: Controlled trial of methenolone acetate in prednisolone-treated rheumatoid arthritic patients. Ann. rheum. Dis. 24, 576–580 (1965).PubMedGoogle Scholar
  686. Wewalka, F.: Anabolika bei chronischen Leberkrankheiten. Z. Gastroenterologie 1, 40–46 (1963).Google Scholar
  687. Wewalka, F.: Anabole Steroide und Leberkrankheiten. Wien. med. Wschr. 117, 293–299 (1967).PubMedGoogle Scholar
  688. Wewalka, F.: Die Behandlung der chronischen Leberkrankheiten mit anabolen Steroiden. Therapiewoche 18, 766–770 (1968).Google Scholar
  689. Whyte, H.M.: Potential effect on coronary-heart-disease morbidity of lowering the blood-cholesterol. Lancet 1975I, 906–910.Google Scholar
  690. Wiggins, R.A.: Observations of the use of 19-nortestosterone in patients with oliguric uremia. Sth. med. J. 56, 669–672 (1963).Google Scholar
  691. Wildhirt, E.: Uber die Lebervertraglichkeit von Anabolika. In: Wirkung und Anwendung anaboler Steroide. Berlin: Medicus Verlag 1964.Google Scholar
  692. a.
    Wiles, F.J., Mackintosh, J.: Effect of durabolin in tuberculosis patients. Med. Proc. 8, 56–57 (1962).Google Scholar
  693. Wilk, F., Rausch-Schott, G.: Die Zystinose. Wien. med. Wschr. 121, 349–353 (1971).PubMedGoogle Scholar
  694. Williams, J.S., Stein, J.H., Ferris, T.F.: Nandrolone decanoate therapy for patients receiving hemodialysis. A controlled study. Arch, intern. Med. 134, 289–292 (1974).Google Scholar
  695. Winther, C.: Testosterone and fibrinolytic activity. Scand. J. clin. Lab. Invest. 99, 207–210 (1967).Google Scholar
  696. Winther, O.: Resistance to testosterone as a stimulation of blood fibrinolytic activity in patients with cancer of the breast. Lancet 1970I, 625.Google Scholar
  697. Wolf, H.: Zur Behandlung der Untergewichtigkeit mit einem oral wirksamen Anabolikum. Wien. med. Wschr. 112, 382–384 (1962).PubMedGoogle Scholar
  698. Wolpert, A., Sheppard, C., Merlis, S.: Method for evaluation of behavioural changes in aged hospital patients during anabolic steroid therapy. J. amer. Geriat. Soc. 15, 470–474 (1967).PubMedGoogle Scholar
  699. Wolpert, A., Sheppard, C., Merlis, S.: Body weight as an index of therapeutic effect in anabolic steroid therapy. J. amer. Geriat. Soc. 16, 323–327 (1968).Google Scholar
  700. Wolthuis, F.H.: Balance studies on protein metabolism; significance for the treatment of renal failure. Voeding 24, 372–386 (1963).PubMedGoogle Scholar
  701. Worm, J.: Progressiv muskeldystrofi behandlet met durabolin. Ugeskr. Laeg. 124, 1325–1327 (1962).PubMedGoogle Scholar
  702. Yamase, F., Hatanaka, H.: Effect of anabolic steroid for treatment of pulmonary tuberculosis. Med. J. Mut. Aid Ass. 12, 4 (1963).Google Scholar
  703. Yoshida, H.: Clinical studies on the decholesterolizing effect of anadrol. Saishin Igaku 20, 2991–2997 (1965).Google Scholar
  704. Zeneroli, M. L.: Sulle variazione della colesterolemia durante trattamenti prolungati con metan-drostenolone, ossimesterone e nandrolone. Endocr. Sci. Const. 31, 107–114 (1970).Google Scholar
  705. Zorrilla, E., Magos, C., Serrano, P. A.: Efecto de la oxandrolona sobre los lipidos sericos en las hiperlipidemias primarias tipo IV y IIb. Arch. Inst. Cardiol. Méx. 43, 270–278 (1973).PubMedGoogle Scholar
  706. Zwozukiak, W., Zgorzalewicz, B.: Early and distant results of the treatment with the anabolic steroids of the progressive muscular dystrophy. Neurol. Neurochir. pol. 1, 345–351 (1967).Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1976

Authors and Affiliations

  • H. Kopera

There are no affiliations available

Personalised recommendations